Substituted imidazopyridines as inhibitors of plasma kallikrein and their uses

Substituted imidazopyridine compounds target plasma kallikrein to inhibit its activity, addressing the excessive bradykinin production in HAE, thereby reducing the severity of swelling attacks and improving treatment outcomes.

JP7590183B2Active Publication Date: 2024-11-26TAKEDA PHARMA CO LTD

Patent Information

Application Number
JP2020548735
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-08
Filing Date
2019-03-12
Publication Date
2024-11-26
Estimated Expiration
2039-03-12

AI Technical Summary

Technical Problem

Hereditary angioedema (HAE) is caused by a deficiency or dysfunction of C1 inhibitor, leading to excessive bradykinin production and debilitating swelling attacks, with a high mortality rate if untreated.

Method used

Development of substituted imidazopyridine compounds that bind to plasma kallikrein to inhibit its activity, thereby reducing bradykinin production and alleviating HAE symptoms.

Benefits of technology

The compounds effectively inhibit plasma kallikrein, potentially reducing the severity and frequency of HAE attacks, thereby improving patient outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590183000001
    Figure 0007590183000001
  • Figure 0007590183000002
    Figure 0007590183000002
  • Figure 0007590183000003
    Figure 0007590183000003
Patent Text Reader

Abstract

The invention provides compounds and compositions useful as inhibitors of plasma kallikrein and exhibiting desirable inhibitor properties. In some embodiments, the present disclosure is based, at least in part, on the development of a number of compounds that bind to plasma kallikrein and effectively inhibit its activity. Accordingly, provided herein are compounds and uses thereof for targeting pKal and / or treating diseases or disorders mediated by pKal.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Plasma kallikrein (pKal) is a serine protease zymogen in blood that is converted to its catalytically active form by coagulation factor XIIa and contributes to the innate inflammatory response and the intrinsic blood coagulation cascade. Mechanisms leading to activation of this pathway in vivo include interaction with polyphosphate released from activated platelets and the lack of C1 inhibitor (C1-INH), the main physiological inhibitor of pKal. pKal-mediated cleavage of high-molecular-weight kininogen generates bradykinin (BK), a potent vasodilator and pro-inflammatory nonapeptide, which activates the bradykinin 2 receptor. Subsequent cleavage of BK by carboxypeptidases generates des-Arg9-BK, which activates the B1 receptor. B1 and B2 receptors are expressed by vascular, glial, and neuronal cell types, with the highest levels of retinal expression detected in the ganglion cell layer and the inner and outer nuclear layers. Activation of B1 and B2 receptors causes vasodilation and increases vascular permeability. [Background technology]

[0002] pKal is also associated with numerous disorders, including hereditary angioedema (HAE), an autosomal dominant disease characterized by painful, unpredictable, recurrent inflammatory attacks affecting the hands, feet, face, abdomen, genitourinary tract, and larynx. The prevalence of HAE is uncertain but estimated to be approximately 1 case per 50,000 people, with no known differences between racial groups. HAE is caused by a deficiency (type I) or dysfunction (type II) of C1-INH, which inhibits pKal, bradykinin, and other serine proteases in the blood. Individuals with hereditary angioedema (HAE) lack C1-INH, resulting in excessive bradykinin production, which in turn leads to painful, debilitating, and potentially fatal swelling attacks. Left untreated, HAE can result in a mortality rate as high as 40%, primarily due to upper airway obstruction. Summary of the Invention [Means for solving the problem]

[0003] The present disclosure is based, at least in part, on the development of a number of compounds that bind to and effectively inhibit the activity of plasma kallikrein. Accordingly, provided herein are compounds and uses thereof for targeting pKal and / or treating diseases or disorders mediated by pKal.

[0004] In some embodiments, the present invention provides a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof, wherein Cy A , Cy B , L, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 Each of these is defined and described in classes and subclasses herein. In certain embodiments, the invention provides compounds of formulas (I)-(V), as defined and described in classes and subclasses herein.

[0005] In some embodiments, the present invention also provides methods of using the compounds of Formulas (I)-(V). The present invention provides, for example, the following items. (Item 1) Formula (I): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur. A is 0 to 4 R A is substituted with a group, Each R A are halogens, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R)-N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N(R) 2 , or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, B is 0 to 5 R B is substituted with a group, Each R B are halogens, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R)-N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N(R) 2 , or C 1~6 L is independently selected from an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; 2 -, -C(R) 2 Q-, -QC(Q)-, -C(Q)Q-, -C(R) 2 QC(O)- and -C(O)QC(R) 2 -, and each Q is independently, where valence allows, a monovalent or divalent group selected from the group consisting of O, N(R), or (S); R 1 、R 2 、R 3 , and R 4 is hydrogen and C 1~6 are independently selected from aliphatic, R 5 、R 6 、R 7 、R 8 , and R 9 are hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2 R, -C(O)N(R) 2 , -NO 2 , -N(R)-N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N(R) 2 , or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two R groups on the same carbon or nitrogen atom are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; The compound or a pharmaceutically acceptable salt thereof, provided that the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide. (Item 2) The compound has the formula (IV):

change

change

change

change

change

change

change

change

change

change

change

change

change

[0006] A.Definition Compounds of the present invention include those generally described above and those further exemplified by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise specified. For purposes of this invention, chemical elements are defined as defined in the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th In addition, general principles of organic chemistry are identified in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry," 5 th Ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.

[0007] Abbreviations used herein have their ordinary meaning within the chemical and biological arts. The chemical structures and formulas set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

[0008] As used herein, the term "aliphatic" or "aliphatic group" means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that may be fully saturated or may contain one or more units of unsaturation, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic (also referred to herein as a "carbocyclyl," "alicyclic," or "cycloalkyl"), and has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocyclyl" or "cycloalkyl") refers to a monocyclic C3-C7 hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, straight-chain or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.

[0009] The term "heteroatom" refers to one or more oxygen, sulfur, nitrogen, phosphorus, or silicon (any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocycle, e.g., N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (including N-substituted pyrrolidinyl).

[0010] As used herein, the term "unsaturated" means that a moiety has one or more units of unsaturation.

[0011] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH) n -, where n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene group hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0012] The term "halogen" means F, Cl, Br, or I.

[0013] The term "aryl" refers to monocyclic and bicyclic ring systems having a total of 5 to 10 ring members, wherein at least one ring in the system is aromatic and each ring in the system has 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring." In some embodiments, an 8- to 10-membered bicyclic aryl group is an optionally substituted naphthyl ring. In certain embodiments of the present invention, "aryl" refers to an aromatic ring system that may have one or more substituents, including, but not limited to, phenyl, biphenyl, naphthyl, anthracyl, and the like. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as, for example, indanyl, phthalimidyl, naphthalimidyl, phenanthridinyl, or tetrahydronaphthyl.

[0014] The terms "heteroaryl" and "heteroar-" refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms, having 6, 10, or 14 pi electrons shared in a cyclic arrangement, and having 1 to 5 heteroatoms in addition to the carbon atoms. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. As used herein, the terms "heteroaryl" and "heteroar-" also include groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups can be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include rings that are optionally substituted.

[0015] As used herein, the terms "heterocyclyl," "heterocyclic radical," and "heterocycle" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated and that, in addition to carbon atoms, has one or more, preferably one to four, heteroatoms as defined above. In this context, the term "nitrogen," when used in reference to a ring atom, includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0 to 3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or + It may be NR (as in N-substituted pyrrolidinyl).

[0016] A heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocyclyl," "heterocyclyl ring," "heterocyclic group," "heterocyclic moiety," and "heterocyclic radical" are used interchangeably herein and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. Heterocyclyl groups can be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, where the alkyl and heterocyclyl moieties independently are optionally substituted.

[0017] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as defined herein.

[0018] As used herein, and unless otherwise stated, the suffix "-ene" is used to represent a divalent group. Thus, any of the above terms can be modified with the suffix "-ene" to describe a divalent version of that moiety. For example, a divalent carbocycle is a "carbocyclylene," a divalent aryl ring is an "arylene," a divalent benzene ring is a "phenylene," a divalent heterocycle is a "heterocyclylene," a divalent heteroaryl ring is a "heteroarylene," a divalent alkyl chain is an "alkylene," a divalent alkenyl chain is an "alkenylene," a divalent alkynyl chain is an "alkynylene," etc.

[0019] As described herein, compounds of the invention may contain "optionally substituted" moieties, if specified. In general, the term "substituted," whether preceded by the term "optionally," means that one or more hydrogens of the specified moiety have been replaced with a suitable substituent. Unless otherwise specified, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at all positions. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that remain substantially unchanged when subjected to conditions that allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0020] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently: halogen; -(CH) 0~4 R°;-(CH2) 0~4 OR°;-O(CH2) 0~4 R°, -O(CH2) 0~4 C(O)OR°;-O(CH2) 0~4 OR°;-(CH2) 0~4 CH(OR°)2;-(CH2) 0~4 SR°; optionally substituted with R° -(CH2) 0~4 Ph; optionally substituted with R° -(CH2) 0~4 O(CH2) 0~1 Ph; optionally substituted with R° -CH=CHPh; optionally substituted with R° -(CH2) 0~4 O(CH2) 0~1 -pyridyl; -NO2; -CN; -N3; ​​-(CH2) 0~4 N(R°)2;-(CH2) 0~4 N(R°)C(O)R°;-N(R°)C(S)R°;-(CH2) 0~4 N(R°)C(O)NR°2;-N(R°)C(S)NR°2;-(CH2) 0~4 N(R°)C(O)OR°;-N(R°)N(R°)C(O)R°;-N(R°)N(R°)C(O)NR°2;-N(R°)N(R°)C(O)OR°;-(CH2) 0~4 C(O)R°;-C(S)R°;-(CH2) 0~4 C(O)OR°;-(CH2) 0~4 C(O)SR°;-(CH2) 0~4 C(O)OSiR°3;-(CH2) 0~4 OC(O)R°;-OC(O)(CH2) 0~4 SR°, -SC(S)SR°;-(CH2) 0~4 SC(O)R°;-(CH2) 0~4 C(O)NR°2;-C(S)NR°2;-C(S)SR°;-SC(S)SR°, -(CH2) 0~4 OC(O)NR°2;-C(O)N(OR°)R°;-C(O)C(O)R°;-C(O)CH2C(O)R°;-C(NOR°)R°;-(CH2) 0~4 SSR°;-(CH2) 0~4S(O)2R°;-(CH2) 0~4 S(O)2OR°;-(CH2) 0~4 OS(O)2R°;-S(O)2NR°2;-(CH2) 0~4 S(O)R°;-N(R°)S(O)2NR°2;-N(R°)S(O)2R°;-N(OR°)R°;-C(NH)NR°2;-P(O)2R°;-P(O)R°2;-OP(O)R°2;-OP(O)(OR°)2;SiR°3;-(C 1~4 straight or branched chain alkylene)ON(R°)2; or -(C 1~4 straight or branched chain alkylene)C(O)ON(R°)2, where each R° may be optionally substituted as defined below and independently represents hydrogen, C 1~6 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, -CH2- (a 5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, two independent occurrences of R° together with the atom(s) between them form a 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0021] Suitable monovalent substituents on R° (or the ring formed by two independent occurrences of R° together with the atoms interposed therebetween) are independently halogen, —(CH2), 0~2 R ● ,-(Halo R ● ), -(CH2) 0~2 OH, -(CH2) 0~2 OR ● , -(CH2) 0~2 CH(OR ● )2;-O(HaloR ● ), -CN, -N3, -(CH2) 0~2 C(O)R ● , -(CH2) 0~2 C(O)OH, -(CH2) 0~2 C(O)OR● , -(CH2) 0~2 SR ● , -(CH2) 0~2 SH, -(CH2) 0~2 NH2, -(CH2) 0~2 NHR ● , -(CH2) 0~2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. -C(O)SR ● , -(C 1~4 Straight or branched chain alkylene)C(O)OR ● , or -SSR ● where each R ● is unsubstituted or, if preceded by "halo", is substituted with one or more halogens only, and C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0022] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =O, =S, =NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2~3 O-, or -S(C(R * 2)) 2~3 S-, wherein each R * is hydrogen, optionally substituted as defined below. 1~6An unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having an aliphatic or 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Preferred divalent substituents attached to adjacent substitutable carbon atoms of an "optionally substituted" group include -O(CR * 2) 2~3 O-, wherein each R * is hydrogen, optionally substituted as defined below. 1~6 It is selected from an aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0023] R * Suitable substituents on the aliphatic group include halogen, -R ● ,-(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, wherein each R ● is unsubstituted or, if preceded by "halo", is substituted with only one or more halogens, and independently represents C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0024] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CHC(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR †2. -C(NH)NR † 2, or -N(R † )S(O)2R † wherein each R † are independently hydrogen, optionally substituted as defined below, C 1~6 an aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, regardless of the above definitions, R † two independent occurrences of together with the atom(s) between them form an unsubstituted 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0025] R † Suitable substituents on the aliphatic group are independently halogen, —R ● ,-(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, where each R ● is unsubstituted or, if preceded by "halo", is substituted with only one or more halogens, and independently represents C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0026] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., and is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference.

[0027] In certain embodiments, the neutral forms of the compounds are regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. In some embodiments, the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0028] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Accordingly, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the compounds of the invention are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium, or 13 C-enriched carbon or 14 Compounds having the present structures including the replacement of a carbon with a C-enriched carbon are within the scope of the present invention. Such compounds are useful, for example, as analytical tools in biological assays, as probes, or as therapeutic agents according to the present invention.

[0029] As used herein, the term "oxo" means an oxygen that is double bonded to a carbon atom, thereby forming a carbonyl.

[0030] symbol" [ka] " indicates the point of attachment of a chemical moiety to the rest of the molecule or chemical formula, except when used as a bond to indicate unknown or mixed stereochemistry.

[0031] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0032] A "dosing regimen" (or "optimal treatment regimen"), as that term is used herein, is a set of unit doses (typically two or more) that are administered individually to a subject, typically spaced apart by a period of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen that requires one or more doses. In some embodiments, the dosing regimen is made up of multiple doses, each spaced apart by the same length of time from each other; in some embodiments, the dosing regimen is made up of multiple doses, with at least two different time periods separating the individual doses.

[0033] As understood from the context, a "reference" sample or subject is a sample or subject that is sufficiently similar to the particular sample or subject of interest to allow for a relevant comparison. In some embodiments, information about the reference sample is obtained simultaneously with information about the particular sample. In some embodiments, the information about the reference sample is a medical history. In some embodiments, the information about the reference sample is stored, for example, on a computer-readable medium. In some embodiments, comparison of the particular sample of interest with the reference sample establishes identity, similarity, or difference between the particular sample of interest compared to the reference material.

[0034] As used herein, the term "sample" refers to a biological sample obtained or derived from a source of interest, as described herein. In some embodiments, the source of interest includes an organism, such as an animal or a human. In some embodiments, the biological sample includes a biological tissue or biological fluid. In some embodiments, the biological sample may be or include bone marrow; blood, e.g., whole blood; blood cells; ascites; tissue or fine needle biopsy sample; cell-containing body fluids; free-floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymphatic fluid; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavage fluids, such as ductal lavage or bronchoalveolar lavage; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and / or excretions; and / or cells derived therefrom, etc. In some embodiments, a biological sample is or comprises cells obtained from a subject. In some embodiments, the obtained cells are or comprise cells derived from the subject from whom the sample is obtained. In some embodiments, a sample is a "primary sample" obtained directly from a source of interest by any suitable means. For example, in some embodiments, a primary biological sample is obtained by a method selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of bodily fluids (e.g., blood (e.g., whole blood), lymph, feces, etc.), and the like. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing a primary sample (e.g., by removing one or more components of the primary sample and / or adding one or more agents), such as filtration using a semipermeable membrane. Such a "processed sample" can include, for example, nucleic acids or proteins extracted from a sample or obtained by subjecting the primary sample to techniques such as, for example, amplification or reverse transcription of mRNA, isolation and / or purification of specific components, etc.

[0035] As used herein, the phrase "therapeutic agent" refers to any agent that has a therapeutic effect and / or induces a desired biological and / or pharmacological effect when administered to a subject.

[0036] As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic agent that confers a therapeutic effect on the treated subject at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect can be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject gives an indication of or feels an effect). In particular, a "therapeutically effective amount" refers to an amount of a therapeutic agent that is effective to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a therapeutic or prophylactic effect that is detectable, for example, by improving symptoms associated with the disease, preventing or delaying the onset of the disease, and / or reducing the severity or frequency of symptoms of the disease. A therapeutically effective amount is generally administered in a dosage regimen that may consist of multiple unit doses. For any particular therapeutic agent, the therapeutically effective amount (and / or an appropriate unit dose within an effective dosage regimen) may vary depending, for example, on the route of administration and combination with other pharmaceutical agents. Additionally, the therapeutically effective amount (and / or unit dose) specific for any particular subject may depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the particular therapeutic agent used; the particular composition used; the age, weight, health, sex, and diet of the subject; the time of administration, route of administration, and / or excretion or metabolic rate of the particular therapeutic agent used; the duration of treatment; and similar factors known in the medical arts.

[0037] As used herein, the term "treatment" (also "treat" or "treating") refers to any administration of a substance (e.g., a provided composition) that partially or completely relieves, ameliorates, alleviates, inhibits, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms, characteristics, and / or causes of a particular disease, disorder, and / or condition. Such treatment may be of subjects who do not exhibit symptoms of the associated disease, disorder, and / or condition and / or who exhibit only early symptoms of the disease, disorder, and / or condition. Alternatively or additionally, such treatment may be of subjects who exhibit one or more established symptoms of the associated disease, disorder, and / or condition. In some embodiments, treatment may be of subjects who have been diagnosed with the associated disease, disorder, and / or condition. In some embodiments, treatment may be of subjects known to have one or more susceptibility factors that statistically correlate with an increased risk of developing the associated disease, disorder, and / or condition.

[0038] B. Compound In some embodiments, provided compounds have formula (I): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur. A is 0 to 4 R A is substituted with a group, Each R Ais halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, B is 0 to 5 R B is substituted with a group, Each R B is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; L is selected from -QC(R)2-, -C(R)2Q-, -QC(Q)-, -C(Q)Q-, -C(R)2QC(O)-, and -C(O)QC(R)2-, where each Q is independently a monovalent or divalent group, where valency allows, selected from the group consisting of O, N(R), or (S); R 1 , R 2 , R 3 , and R 4 is hydrogen and C 1~6 are independently selected from aliphatic, R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two R groups on the same carbon or nitrogen atom are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; However, the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0039] In some embodiments, provided compounds, or pharmaceutically acceptable salts thereof, have the structure of Formula (I), wherein: A is a group other than pyridinediyl, and the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0040] In some embodiments, Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy is A is 0 to 4 R A is substituted with a group.

[0041] In some embodiments, Cy A is selected from 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy is A is 0 to 4 R A is substituted with a group.

[0042] In some embodiments, Cy A is a 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0043] In some embodiments, Cy A is a 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, where Cy A is 0 to 3 R A In some embodiments, Cy is substituted with a group. A is a 6-membered heteroarylene having one nitrogen atom, where Cy A is 0 to 3 R A In some embodiments, Cy is substituted with a group. A is pyridinediyl. In some embodiments, Cy A is the following: [ka] is selected from either where * represents the point of attachment to L.

[0044] In some embodiments, Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy A is 0 to 2 R A In some embodiments, Cy is substituted with a group. A is 0 to 3 R AIn some embodiments, Cy is a pyrrolediyl substituted with a methyl group. A is 0 to 2 R A In some embodiments, Cy is a pyrazoldiyl substituted with a group. A is 0 to 1 R A In some embodiments, Cy is a triazolediyl substituted with a cysteine ​​group. A is 0 to 1 R A In some embodiments, Cy is a thiazoldiyl substituted with a thiazol-1-yl group. A is unsubstituted tetrazolediyl. In some embodiments, Cy A is unsubstituted oxadiazoldiyl. In some embodiments, Cy A is unsubstituted thiadiazoldiyl. In some embodiments, Cy A is 0 to 2 R A In some embodiments, Cy is an imidazolediyl substituted with a group. A is 0 to 1 R A In some embodiments, Cy is an oxazoldiyl substituted with a group. A is 0 to 1 R A isoxazoldiyl substituted with a group.

[0045] In some embodiments, Cy A is a 7-10 membered bicyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy A is 0 to 4 R A In some embodiments, Cy is substituted with a group. A is a 9-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy A is 0 to 4 R A In some embodiments, Cy is substituted with a group. A is a 9-membered bicyclic heteroarylene having two nitrogen atoms, where Cy A is 0 to 4 R A In some embodiments, Cy is substituted with a group. A is 0 to 4 RA and pyrrolopyridinediyl substituted with a group.

[0046] In some embodiments, Cy A is the following: [ka] [ka] is selected from the group consisting of where * represents the point of attachment to L.

[0047] In some embodiments, each R A is C 1~6 Independently selected from optionally substituted groups selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0048] In some embodiments, optionally substituted R A The substituents on the group are independently halogen, (CH2) 0~4 R°, -(CH2) 0~4 OR°; and -(CH2) 0~4 C(O)OR°, where each R° is independently hydrogen, C 1~6 It is an aliphatic or 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0049] In some embodiments, R A One example is halogen-substituted C 1~6 It is aliphatic.

[0050] In some embodiments, R A One example is -(CH2) 0~4 C substituted with OR° 1~6aliphatic, where R° is hydrogen or C 1~6 It is aliphatic.

[0051] In some embodiments, R A One example is -(CH2) 0~4 C substituted with C(O)OR° 1~6 aliphatic, where R° is hydrogen or C 1~6 It is aliphatic.

[0052] In some embodiments, R A One example of is a C substituted with a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1~6 It is aliphatic.

[0053] In some embodiments, R A One example of is an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R A One example of is optionally substituted cyclopropyl. In some embodiments, R A One example is -(CH2) 0-4 C(O)OR° substituted cyclopropyl, where R° is hydrogen or C 1~6 It is aliphatic.

[0054] In some embodiments, Cy B is selected from 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from phenyl, oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy is B is 0 to 5 R B In some embodiments, Cy is substituted with a group. B is selected from phenyl and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy is B is 0 to 5 R Bis substituted with a group.

[0055] In some embodiments, Cy B is a 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy B is 0 to 5 R B is substituted with a group.

[0056] In some embodiments, Cy B is a 9-membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy B is 0 to 5 R B In some embodiments, Cy is substituted with a group. B is a 9-membered bicyclic heteroaryl having 2-3 nitrogen atoms, where Cy B is 0 to 5 R B In some embodiments, Cy is substituted with a group. B is 0 to 5 R B In some embodiments, Cy is an imidazopyridinyl group substituted with a group. B is 0 to 5 R B In some embodiments, Cy is a pyrazolopyridinyl group substituted with a group. B is 0 to 4 R B In some embodiments, Cy is a pyrrolopyridinyl group substituted with a group. B is 0 to 4 R B In some embodiments, Cy is a triazolopyridinyl group substituted with a group. B is 0 to 4 R B In some embodiments, Cy is an imidazopyrimidinyl group substituted with a group. B is 0 to 4 R B In some embodiments, Cy is an imidazopyridazinyl group substituted with a group. B is 0 to 5 R B In some embodiments, Cy is an indolizinyl group substituted with a cysteine ​​group. B is 0 to 4 R B A pyrazolopyrimidinyl group substituted with a group.

[0057] In some embodiments, Cy B is 0 to 5 R B In some embodiments, Cy is an indolyl group substituted with a cysteine ​​group. B is 0 to 5 R B In some embodiments, Cy is a benzofuranyl group substituted with a benzofuranyl group. B is 0 to 4 R B In some embodiments, Cy is a pyrazolopyrimidinyl group substituted with a group. B is 0 to 4 R B In some embodiments, Cy is a benzimidazolyl group substituted with a methyl group. B is 0 to 4 R B A thienopyridinyl group substituted with a group.

[0058] In some embodiments, Cy B is the following: [ka] is selected from the group consisting of:

[0059] In some embodiments, Cy B is a 10-membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein Cy B is 0 to 5 R B In some embodiments, Cy is substituted with a group. B is a 10-membered bicyclic heteroaryl having one nitrogen, where Cy B is 0 to 5 R B In some embodiments, Cy is substituted with a group. B is 0 to 5 R B In some embodiments, Cy is a quinolonyl group substituted with a hydroxyl group. B is 0 to 5 R B In some embodiments, Cy is a quinoxalinyl group substituted with a hydroxyl group. B is the following: [ka] is selected from the group consisting of:

[0060] In some embodiments, each R B is halogen, -CN, -C(O)R, -C(O)2R, -N(R)2, -OR, or C 1~6 and optionally substituted groups selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, wherein each R is independently selected from hydrogen or C 1~6 It is aliphatic.

[0061] In some embodiments, optionally substituted R B The substituents on the group are halogen, -(CH2) 0~4 OR°, -O(CH2) 0~4 OR°, -(CH2) 0~4 C(O)OR°, and -(CH2) 0~4 N(R°)2, where each R° is independently selected from hydrogen, C 1~6 aliphatic, or two independent occurrences of R° together with the atom(s) between them form an optionally substituted 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be further substituted.

[0062] In some embodiments, R B One example of R is halogen. B One example of is -CN. In some embodiments, R B One example of is -C(O)R, where R is hydrogen or C 1~6 In some embodiments, R B One example of is -C(O)R, where R is hydrogen or C 1~6In some embodiments, R B One example of is -N(R)2, where R is hydrogen or C 1~6 In some embodiments, R B One example of is -OR, where R is hydrogen or C 1~6 It is aliphatic.

[0063] In some embodiments, R B One example is -(CH2) 0~4 C substituted with OR° 1~6 aliphatic, where R° is hydrogen or C 1~6 It is aliphatic.

[0064] In some embodiments, R B One example is -O(CH2) 0~4 C substituted with OR° 1~6 aliphatic, where R° is hydrogen or C 1~6 It is aliphatic.

[0065] In some embodiments, R B One example is -(CH2) 0~4 C substituted with C(O)OR° 1~6 aliphatic, where R° is hydrogen or C 1~6 It is aliphatic.

[0066] In some embodiments, R B One example of is an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R B One example of is optionally substituted cyclopropyl. In some embodiments, R B One example is -(CH2) 0~4 Cyclopropyl substituted with OR°, where R° is hydrogen or C 1~6 In some embodiments, R B One example is -(CH2) 0~4 Cyclopropyl substituted with C(O)OR°, where R° is hydrogen or C 1~6 It is aliphatic.

[0067] In some embodiments, R B One example of R is an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B One example of is an optionally substituted 4-membered saturated monocyclic heterocyclyl having one oxygen. In some embodiments, R B One example has one oxygen, -(CH2) 0~4 a 4-membered saturated monocyclic heterocyclyl substituted by OR°, where R° is hydrogen or C 1~6 It is aliphatic.

[0068] In some embodiments, R B One example is -(CH2) 0~4 C substituted with N(R°)2 1~6 aliphatic, where two independent occurrences of R° together with the atom(s) between them form an optionally substituted 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be further substituted. B One example is -(CH2) 0~4 C substituted with N(R°)2 1~6 Aliphatic, wherein the two independent occurrences of R° together with the atom(s) between them form a 5-membered saturated monocyclic ring, optionally substituted and further substituted with ═O.

[0069] In some embodiments, L is selected from -QC(R)2-, -C(R)2Q-, -C(Q)Q-, or -C(R)2QC(O)-, where Q is independently selected from O, N(R), or (S), a monovalent or divalent group, where valences permit. In some embodiments, L is selected from -QC(R)2-, -C(R)2Q-, -C(Q)Q-, or -C(R)2QC(O)-, where Q is independently selected from O or N(R), a monovalent or divalent group, where valences permit. In some embodiments, L is selected from the following: [ka] is selected from the group consisting of In the formula, # represents the point of attachment to CyA. In some embodiments, L is -N(H)C(O)-. In some embodiments, L is -C(O)N(H)-.

[0070] In some embodiments, R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -N(R)2, -OR, or C 1~6 an optionally substituted group selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, wherein each R is independently hydrogen or C 1~6 In some embodiments, R 5 , R 8 , and R 9 is hydrogen.

[0071] In some embodiments, R 6 is selected from hydrogen or halogen. In some embodiments, R 6 is hydrogen. In some embodiments, R 6 is halogen. In some embodiments, R 6 is F. In some embodiments, R 6 is Cl. In some embodiments, R6 is Br. In some embodiments, R 6 is I.

[0072] In some embodiments, R 7 is a halogen or an optionally substituted C 1~6 In some embodiments, R 7 is halogen. In some embodiments, R 7 is F. In some embodiments, R 7 is Cl. In some embodiments, R 7 is Br. In some embodiments, R 7 is I. In some embodiments, R 7 is an arbitrarily substituted C 1~6 In some embodiments, R 7 is an arbitrarily substituted C 1~5 In some embodiments, R 7 is an arbitrarily substituted C 1~4 In some embodiments, R 7 is an arbitrarily substituted C 1~3 In some embodiments, R 7 is an arbitrarily substituted C 1~2 In some embodiments, R 7 is alkynyl.

[0073] In some embodiments, provided compounds have formula (II): [ka] or a pharmaceutically acceptable salt thereof, wherein Cy A , Cy B , R 1 , R 2 , R 6 , and R 7 each of which is defined and described in classes and subclasses herein; However, the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0074] Unless otherwise specified or prohibited by the preceding definition of formula (II), the variable Cy is defined above and described in classes and subclasses herein. A , Cy B , R 1 , R 2 , R 6 , and R 7 It will be understood that the above embodiment also applies to compounds of formula (II), both alone and in combination.

[0075] In some embodiments, provided compounds, or pharmaceutically acceptable salts thereof, have the structure of Formula (II): A is a group other than pyridinediyl, and the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6yl)methyl)isonicotinamide.

[0076] In some embodiments, provided compounds or pharmaceutically acceptable salts thereof are represented by formula (III-a), formula (III-b), formula (III-c), formula (III-d), [ka] having the structure In the formula, R A , Cy B , R 1 , R 2 , R 6 , and R 7 Each of the following is defined and described in classes and subclasses herein.

[0077] Unless otherwise specified or prohibited by the preceding definition of formula (III), the variable moiety R is defined above and described in classes and subclasses herein.A , Cy B , R 1 , R 2 , R 6 , and R 7 It will be understood that the above embodiment also applies to compounds of formula (III-a), formula (III-b), formula (III-c), and formula (III-d), both alone and in combination.

[0078] In some embodiments of formulas (I), (II), (III-a), (III-b), (III-c), and (III-d), Cy B teeth, [ka] and During the ceremony, W 1 , W 2 , W 3 , and W 4 are independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14 are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, two R groups on the same carbon or nitrogen atom are joined together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0079] In some embodiments, W 1 is nitrogen, and W 2 , W 3 , and W 4 is carbon. In some embodiments, W 2 is nitrogen, and W 1 , W 3 , and W 4 is carbon. In some embodiments, W 2 and W 3 is nitrogen, and W 1 and W 4 is carbon. In some embodiments, W 2 and W 4 is nitrogen, and W 1 and W 3 is carbon.

[0080] In some embodiments of formulas (I), (II), (III-a), (III-b), (III-c), and (III-d), Cy B teeth, [ka] and During the ceremony, W2 is selected from carbon, nitrogen, oxygen, and sulfur; W 1 , W 3 , and W 4 are independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14 are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, two R groups on the same carbon or nitrogen atom are joined together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0081] In some embodiments, provided compounds have formula (IV): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen or nitrogen, and Cy A is 0 to 3 R A is substituted with a group, Each R A is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; L is selected from -NC(O)- and -C(O)N-; R 6 , R 8 , and R 9is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 7 is -F, -Cl, or -Br, W 4 is carbon or nitrogen, R 10 and R 11 are each optionally present and, if present, are selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 13is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 2~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 14 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 3~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, two R groups on the same carbon or nitrogen atom are joined together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0082] In some embodiments, Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen or nitrogen. A is a 5-membered heteroarylene having 1 to 4 nitrogen atoms. A is a 5-membered heteroarylene having 1 to 4 nitrogen atoms, where Cy A When Cy contains three nitrogens, it is not 1,2,4-triazolediyl. A is a 5-membered heteroarylene having 1 to 3 nitrogen atoms. A is a 5-membered heteroarylene having 1 to 2 nitrogen atoms. A is a 5-membered heteroarylene having one nitrogen atom. A is a 5-membered heteroarylene having two nitrogen atoms. A is a 5-membered heteroarylene having 3 nitrogen atoms. A is a five-membered heteroarylene having four nitrogens.

[0083] In some embodiments, Cy Ais the following: [ka] is selected from the group consisting of where * represents the point of attachment to L.

[0084] In some embodiments, W 4 is carbon. In some embodiments, W 4 is nitrogen.

[0085] In some embodiments, R 11 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 and optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0086] In some embodiments, R 13is -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R , -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N (R)2 or an optionally substituted group selected from phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0087] In some embodiments, R 13 is a halogen, optionally substituted C 1~6 It is selected from aliphatic and optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.

[0088] In some embodiments, R 13 is halogen. In some embodiments, R 13 is -F. In some embodiments, R 13 is —Cl. In some embodiments, R 13 is -Br. In some embodiments, R 13 is -I.

[0089] In some embodiments, R 13 is an arbitrarily substituted C 1~6 In some embodiments, R 13 is an arbitrarily substituted C 1~5 In some embodiments, R 13 is an arbitrarily substituted C 1~4 In some embodiments, R 13 is an arbitrarily substituted C 1~3 In some embodiments, R 13is an arbitrarily substituted C 1~2 It is aliphatic.

[0090] In some embodiments, R 13 is an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted 3- or 5- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted 6-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted 5-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted 4-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted 3-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 13 is an optionally substituted cyclopropyl.

[0091] In some embodiments, provided compounds have formula (V): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 nitrogen atoms, and Cy A If contains three nitrogens, it is [ka] Instead, L is selected from -NC(O)- and -C(O)N-; R 6, R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 7 is -F, -Cl, or -Br, R 10 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 11is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 13 is -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R )2, or an optionally substituted group selected from phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- or 5- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 14 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C3~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, two R groups on the same carbon or nitrogen atom are joined together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0092] In some embodiments, provided compounds include N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)isonicotinamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide 1-((6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-isopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide , N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((6-methoxyimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a ]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[ 1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((7-chloro- 6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5,6-dimethylimidazo[1 ,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5- a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxamide, N-((7,8-dichloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide 1-((6-chloro-5-ethylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-methylimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-7-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro 1-((6-bromo-7-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)thiazole-5-carboxamide, 1-((6-bromo-5- chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-5-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-(2,2-dimethylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-(2-methylprop-1-en-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(2-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7- Bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(2-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-iodoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-ethylimidazo[1,2-a]pyridin-2-yl)methyl)- (Z)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(prop-1-en-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-cyclopropylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-Oxadiazole-2-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((6-aminoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo, [1,5-a]pyridin-1-yl)methyl)-1-((5-cyanoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyanoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazo methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((5-amino-7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-( (6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclobutylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4 -carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methoxyimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)propanoic acid methyl ester, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-ethynylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1- ((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-ethylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-yl methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-thiadiazole-2-carboxamide, ethyl 2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate, ethyl 2-((4-(((7-chloroimidazo [1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid, 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)propanoic acid, N-(1-(7-bromoimidazo[1,5-a]pyridin-1-yl)ethyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-(( 7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-(methylamino)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-3-cyclopropyl-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5 -ethynylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin methyl 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-5-yl)propanoate, methyl N-((7-bromo-3-(difluoromethyl)imidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-3-cyclopropyl-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H -pyrazole-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxyethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-amino-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)- 1H-Pyrazole-4-carboxamide, 1-((5-amino-8-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl-d2)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-((4-((7-chloroimidazo[1, 5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridine-6-carboxylate, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)propanoic acid ethyl ester, N-(2-(7-chloroimidazo[1,5-a]pyridin-1-yl)ethyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(difluoromethyl)-1H-pyrazole-4-carboxamide , 2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridine-6-carboxylic acid, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-N-((7-ethynylimidazo[1,2-b]pyridazin-2-yl)methyl)- N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(difluoromethyl)-1H-pyrazole-4-carboxamide, 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine- 8-yl)acrylate, ethyl 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoate, ethyl 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(morpholinomethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(oxetan-3-yl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methoxyethoxy)imidazo[1,2-a]pyridin-2-yl)methyl)-1, H-pyrazole-4-carboxamide, 1-((8-acetyl-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-((7-bu 2-(2-((4-(((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetic acid ethyl ester, 2-(2-((4-(((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetic acid ethyl ester, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6- Cyclopropyl-8-(3-hydroxypropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-hydroxy-2-methylpropyl)imidazo[1,2 -a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)cyclopropane-1-carboxylate, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1 -((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridin-8-yl)cyclopropane-1-carboxylate, 1-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1 -yl)methyl)imidazo[1,2-a]pyridin-8-yl)cyclopropane-1-carboxylic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(1-(hydroxymethyl)cyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-vinylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)cyclopropane-1-carboxylic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxyoxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N'-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-N-cyano-1 -((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboximidamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(1-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methoxyethyl)imidazo[1,2-a]pyridin-2 -yl)methyl)-1H-pyrazole-4-carboxamide, 3-((2H-tetrazol-5-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, and N-((7-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-1-((5,6-dimethylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carboxamide) N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1, 2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole- 2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-( (6-cyclopropyl-5-methoxyimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridine- 2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole -4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-6-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1, ,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,4-triazole-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxyoxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2 ,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, 1-((8-((1,3,4-oxadiazol-2-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazo N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, 2-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)ethyl acetate, 2- (2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(methylsulfonyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1-methyl-1H-1,2,4-triazole-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid ethyl ester, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazole-3-carboxamide 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoic acid ethyl ester, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoic acid ethyl ester, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1, 2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate, 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-fluorooxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)methyl 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid ethyl ester, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazo 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide , 1-((6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-morpholinoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5- ((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)isoxazole-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,2,4-oxadiazole-3-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-1H-1 ,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1H-tetrazol-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(4H-1,2,4-triazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-formylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide3-Triazole-4-carboxamide, 1-((8-(3-amino-3-oxopropyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(2-cyanoethyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole Azole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-ylmethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H- 1,2,3-Triazole-4-carboxamide, 1-((6-chloro-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6,7-dichloroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole- 4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylthieno[2,3-b]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-3-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,2,4-oxadiazole-5-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylbenzofuran-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(difluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-, 1-((8-(2-(1H-tetrazol-5-yl)ethyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6 -cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)oxazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-chlorobenzofuran-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(1-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)ethyl)-1H-1,2,3-triazole- 4-Carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxotetrahydrofuran-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazo 1-((8-((1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)-1H-pyrazole-3-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-bromo-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl) 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid ethyl ester, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid ethyl ester 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)ethyl acetate, 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)ethyl acetate )-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)acetic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylpyrazolo[1,5-a]pyrimidin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 5-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)-1,3,4-oxadiazole-2-carboxylate, 1-((8-((1,3,4-oxadiazol-2-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-3-(trifluoromethyl)-2-pyridin-8-yl)methyl)-1H-1,2,3-triazole-4-carboxylate 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)-2-methylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1-fluoro 1-((8-((1,3,4-oxadiazol-2-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxadiazol-2-yl)methyl)- N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxooxazolidin-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylbenzo[b]thiophen-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylbenzofuran-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1H-pyrazol-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl methyl)cyclopentane-1-carboxylate, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)cyclopentane-1-carboxylic acid, 1-((2-((4-(((7-chloro-8-ethoxyimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)cyclopentane-1-carboxylic acid Chloropropylimidazo[1,2-a]pyridin-8-yl)methyl)cyclopentane-1-carboxylic acid, 1-((6-chloro-1H-indol-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)-2-methylpropanoic acid ethyl ester, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-fluoropropanoic acid methyl ester, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl )-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-fluoropropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(isoxazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-(2-((4-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methylcarbamoyl)-1H-1,2,3-triazole-1- 3-(4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)-3-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)propanoic acid ethyl ester, 3-(4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol- 1-yl)-3-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)propanoic acid, 3-(4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)-3-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)propanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylbenzo[b]thiophen-2-yl)methyl)-1H-1,2,3-Triazole-4-carboxamide, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-1H-pyrazole-4-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-, 2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-1H-indol-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-1-methyl-1H-indol-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-1-methyl-1H-indol-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-chlorobenzo[b]thiophen-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-1H-indol-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-1H-indol-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(2-cyano-2-methylpropyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methyl-2-(2 H-tetrazol-5-yl)propyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-3-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-3-hydroxy-2,2-dimethylpropanoic acid ethyl ester, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1 ,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-3-hydroxy-2,2-dimethylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1-ethyl-5,6-dioxo-5,6-dihydro-1,2,4-triazin-4(1H)-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide ... 2-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-5-cyclopropyl-1H-indol-1-yl)acetic acid, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)difluoromethyl)-1,3,4-oxadiazole-2-carboxamide, 2-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-5-cyclopropyl-1H-indol-1-yl)acetic acid, ethyl 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-methylpropanoate, ethyl 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-methylpropanoate, 2-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-5-cyclopropyl-1H-indol-1-yl) methyl acetate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(5,6-dioxo-5,6-dihydro-1,2,4-triazin-4(1H)-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 4-(2-((4 -(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-4H-1,2,4-triazole-3-carboxylate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-methyl-4H-1,2,4-triazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxa-6-azaspiro[3.3]heptan-6-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazole ethyl 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-5-cyclopropyl-1H-indol-1-yl)propanoate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylbenzo[d]thiazol-2-yl)methyl)-1H-1,2,3-Triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 4-(2-((4-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazole-1- 1-((5-chloro-7-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylindolizin-2-yl)methyl)-1H -1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methylthiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-methyl-1H-1,2,4-triazole-1-yl)methyl) 4-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-5-cyclopropyl-1H-indol-1-yl)benzoic acid, 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-2-carboxylate, ethyl 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-2-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-7-(2-oxopyrrolidin-1-yl)pyrazolo[1,5-a]pyridin-2-yl)methyl)- N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(thiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 4-(2-((4-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropyl imidazo[1,2-a]pyridin-8-yl)morpholine-2-carboxylic acid, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)azetidine-3-carboxylate, methyl 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl) methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)azetidine-3-carboxylic acid, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)pyrrolidine-3-carboxylate, methyl 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)pyrrolidine-3-carboxylic acid, 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylindolizine-3-carboxylic acid ethyl ester, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((1,2,3-trimethyl-1H-indol-5-yl)methyl)-1H-1,2,3-triazole-4-carboxylic acid, methyl)-1H-pyrrole-2-carboxylate, methyl 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrole-2-carboxylate, methyl 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrole-2-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropyl-1H-indole-3-carboxylate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-( (6-cyclopropyl-8-(hydroxy(3-(hydroxymethyl)oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-3-cyclopropylquinolin-6-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-((4-((7-chloro-8-fluoroimidazo[1,5-a]pyridine N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,N-((7-chloro-6-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-(1-(7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)ethyl)-1-(1-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)ethyl)-1H-1,2,3-triazo N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-(1-(7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)ethyl)-1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-((N-(2,2,2-trifluoroethyl)sulfamoyl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-([1,2,4]triazolo[1,5-a]pyridin-2-ylmethyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-b]pyridazin-2-ylmethyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-1,2,3-triazole-4-carboxamide, 1-([1,2,4]triazolo[1,5-a]pyridin-2-ylmethyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H -1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-imidazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)- N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-b]pyridazin-2-ylmethyl)-1H-imidazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(quinoxalin-6-ylmethyl)-1H-1,2,3-triazole-4-carboxamide Triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(quinoxalin-6-ylmethyl)-1H-pyrazole-4-carboxamide, 1-((8-(4H-1,2,4-triazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(pyrrolidin-1-ylmethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(oxetan-3-ylmethyl)imidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5- a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-imidazole-4-carboxamide, 1-((8-(aminomethyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-((2 -(dimethylamino)ethoxy)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(((3,3,3-trifluoro-2-hydroxypropyl)amino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a ]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-((2-hydroxyethoxy)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-((2-aminoethoxy)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

[0093] C. Pharmaceutical Compositions In another aspect, the present invention provides pharmaceutical compositions comprising a compound of Formula (I)-(V) or a compound of Formula (I)-(V) in combination with a pharmaceutically acceptable excipient (e.g., carrier).

[0094] The pharmaceutical compositions include optical isomers, diastereomers, or pharmaceutically acceptable salts of the inhibitors disclosed herein. The compounds of Formulas (I)-(III-d) included in the pharmaceutical compositions can be covalently bound to a carrier moiety as described above. Alternatively, the compounds of Formulas (I)-(V) included in the pharmaceutical compositions are not covalently bound to a carrier moiety.

[0095] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutical excipient, e.g., a pharmaceutically and physiologically acceptable organic or inorganic carrier substance suitable for enteral or parenteral administration that does not adversely react with the active agent. Suitable pharmaceutically acceptable carriers include water, salt solutions (e.g., Ringer's solution), alcohol, oils, gelatin, and carbohydrates such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, and polyvinylpyrrolidine. Such preparations may be sterilized and, if necessary, may be mixed with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring agents, and / or flavoring agents, which do not adversely react with the compounds of the present invention.

[0096] The compounds of the present invention can be administered singly or simultaneously. Simultaneous administration is intended to include simultaneous or sequential administration of the compounds individually or in combination (two or more compounds). The preparations can also be combined with other agents, if necessary (e.g., to reduce metabolic degradation).

[0097] In some embodiments, test agents as described herein can be incorporated into pharmaceutical compositions for administration by methods known to those of skill in the art and described herein for the provided compounds.

[0098] D. Formulation The compounds of the present invention can be prepared into a wide variety of oral, parenteral, and topical dosage forms and can be administered in a wide variety of oral, parenteral, and topical dosage forms. Thus, the compounds of the present invention can be administered by injection (e.g., intravenously, intramuscularly, intradermally, subcutaneously, intraduodenally, or intraperitoneally). The compounds described herein can also be administered by inhalation, for example, intranasally. In addition, the compounds of the present invention can be administered transdermally. It is also contemplated that multiple administration routes (e.g., intramuscularly, orally, transdermally) can be used to administer the compounds of the present invention. Thus, the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds of the present invention.

[0099] For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be solid or liquid.Solid preparations include powder, tablets, pills, capsules, cachets, suppositories and dispersible granules.Solid carriers can be one or more substances that can also function as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents or encapsulating materials.

[0100] In powders, the carrier is a finely divided solid in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[0101] Powders and tablets preferably contain 5% to 70% of the active compound. Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low-melting waxes, cocoa butter, and the like. The term "preparation" is intended to include a combination of the active compound with an encapsulating material as a carrier, in which the active ingredient is surrounded by a carrier, with or without other carriers, thereby providing a capsule in which the carrier is associated with the active ingredient. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0102] For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active ingredient is dispersed homogeneously therein as by stirring, etc. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby solidify.

[0103] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water / propylene glycol solutions.For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

[0104] When parenteral administration is required or desired, particularly suitable mixtures for the compounds of the present invention are injectable sterile solutions, preferably oily or aqueous solutions, and suspensions, emulsions, or inserts, including suppositories. Particularly, carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene block polymers, etc. Ampoules are convenient unit doses. The compounds of the present invention can also be incorporated into liposomes or administered via transdermal pumps or patches. Suitable pharmaceutical mixtures for use in the present invention include, for example, those described in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO96 / 05309, the teachings of both of which are incorporated herein by reference.

[0105] Aqueous solutions suitable for oral use can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizers, and thickeners, if desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active ingredient in water together with viscous materials, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

[0106] Also included are solid preparations intended to be converted immediately before use into liquid preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active ingredient, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers, etc.

[0107] Pharmaceutical preparations are preferably in unit dosage form.In this form, the preparation is subdivided into unit doses containing appropriate amounts of active ingredient.The unit dosage form can be a packaged preparation, the package containing discrete amounts of preparation, for example, packaged tablets, capsules, and powders in vials or ampoules.The unit dosage form can be a capsule, tablet, cachet, or lozenge alone, or the appropriate number of any of these in packaged form.

[0108] The quantity of active ingredient in a unit dose preparation may be varied or adjusted from 0.1 mg to 10,000 mg, more usually from 1.0 mg to 1,000 mg, and most usually from 10 mg to 500 mg, depending on the particular use and potency of the active ingredient. The composition may also contain other compatible therapeutic agents, if desired.

[0109] Some compounds may have limited solubility in water and therefore may require a surfactant or other suitable co-solvent in the composition. Such co-solvents include: polysorbates 20, 60, and 80; Pluronic® F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil. Such co-solvents are typically used at levels between about 0.01% and about 2% by weight.

[0110] A viscosity greater than that of a simple aqueous solution may be desirable to reduce variability in dispensing the formulation, to reduce physical separation of the components of a suspension or emulsion formulation, and / or to otherwise improve the formulation. Examples of such viscosity-enhancing agents include polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, chondroitin sulfate and its salts, hyaluronic acid and its salts, and combinations of the foregoing. Such agents are typically used at levels between about 0.01% and about 2% by weight.

[0111] The compositions of the present invention may additionally contain ingredients that provide sustained release and / or comfort. Such ingredients include high molecular weight anionic mucus-mimetic polymers, gelling polysaccharides, and micronized drug carrier substrates. These ingredients are described in more detail in U.S. Patent Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.

[0112] E. Effective Dosage Pharmaceutical compositions provided by the present invention include compositions containing an active ingredient in a therapeutically effective amount, i.e., an amount effective to achieve its intended purpose. The actual amount effective for a particular application will depend, inter alia, on the condition being treated. For example, when administered in a method for treating HAE, such compositions will contain an amount of active ingredient effective to achieve the desired result (e.g., inhibiting pKal and / or reducing the amount of bradykinin in a subject).

[0113] The dosage and frequency (single or multiple doses) of the compound administered can vary depending on a variety of factors, including the route of administration; the size, age, sex, health, weight, body mass index, and diet of the recipient; the nature and extent of symptoms of the disease being treated (e.g., a disease responsive to pKal inhibition); the presence of other diseases or other health-related problems; the type of concomitant treatment; and complications from any disease or treatment regimen. Other therapeutic regimens or agents may be used in conjunction with the methods and compounds of the invention.

[0114] For any provided compound or test agent, the therapeutically effective amount can be initially determined by cell culture assays. The target concentration is the concentration of active compound(s) that can reduce pKal enzyme activity, for example, as measured using the methods described.

[0115] The therapeutically effective amount for use in humans can be determined from animal models. For example, a human dose can be formulated to achieve a concentration that has been found to be effective in animals. The human dosage can be adjusted by monitoring pKal inhibition and adjusting the dosage upward or downward, as described above.

[0116] Dosage may vary depending on the patient's needs and the compound being used. In the context of this invention, the dosage administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose will also be determined by the existence, nature, and extent of any adverse side effects. Generally, treatment is initiated with lower dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In some embodiments, the dosage range is 0.001-10% w / v. In some embodiments, the dosage range is 0.1-5% w / v.

[0117] Dosage amount and interval may be adjusted individually to provide effective levels of the compound being administered for the particular clinical indication being treated, thereby providing a treatment regimen commensurate with the severity of the individual disease state.

[0118] F. Treatment Method The present disclosure provides compounds for use in medicine. The present disclosure further provides the use of any compound described herein to inhibit the activity of pKal, which is beneficial in treating diseases and conditions mediated by pKal. Exemplary disorders mediated by pKal include edema, which refers to swelling in a subject's entire body or part of it due to inflammation or injury when small blood vessels become leaky and release fluid into surrounding tissues. In some examples, the edema is HAE. In other examples, the edema occurs in the eye (e.g., diabetic macular edema (DME)). The present disclosure provides methods for inhibiting the activity of pKal. In certain embodiments, the present application provides methods for inhibiting the activity of pKal in vitro by contacting any of the compounds described herein with pKal molecules in a sample, e.g., a biological sample. In certain embodiments, the present application provides methods for inhibiting the activity of pKal in vivo by delivering an effective amount of any of the compounds described herein to a subject in need of treatment via a suitable route.

[0119] In certain embodiments, the methods comprise administering any of the compounds described herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof (e.g., a subject, such as a human patient, having edema). In certain embodiments, the methods comprise administering a compound of Formula (I)-(V), or a pharmaceutically acceptable salt or composition thereof, to a subject in need thereof. In some embodiments, the methods comprise administering a pharmaceutical composition comprising a compound of Formula (I)-(V) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0120] In certain embodiments, the subject treated by any of the methods described herein is a human patient who has, is suspected of having, or is at risk of having edema, such as HAE or diabetic macular edema (DME).Subjects with edema can be identified by routine medical examination, for example, clinical examination.Subjects suspected of having edema can show one or more symptoms of disease / disorder.Subjects at risk of edema can have one or more of the risk factors associated with disease, for example, C1-INH deficiency for HAE.

[0121] In certain embodiments, provided herein are methods for alleviating one or more symptoms of HAE in a human patient suffering from an HAE attack. Such patients can be identified through routine medical procedures. An effective amount of one or more of the provided compounds can be administered to a human patient by a suitable route, such as those described herein. The compounds described herein can be used alone or in combination with other anti-HAE agents, such as C1 esterase inhibitors (e.g., Cinryze® or Berinert®), pKal inhibitors (e.g., ecallantide or lanadelumab), or bradykinin B2 receptor antagonists (e.g., Firazyr®).

[0122] In another embodiment, provided herein is a method for reducing the risk of HAE attacks in human HAE patients in a quiescent state. Such patients can be identified based on various factors, including a history of HAE attacks. An effective amount of one or more of the compounds of the present invention can be administered to a human patient by a suitable route, such as those described herein. The compounds described herein can be used alone or in combination with other anti-HAE agents, such as C1 esterase inhibitors (e.g., Cinryze® or Berinert®), pKal inhibitors (e.g., ecallantide or lanadelumab), or bradykinin B2 receptor antagonists (e.g., Firazyr®).

[0123] In yet another embodiment, provided herein is the prophylactic treatment of HAE in human patients at risk for HAE attacks using one or more of the compounds described herein. Patients suitable for such prophylactic treatment may be human subjects with a history of HAE attacks (e.g., human subjects experiencing more than two attacks per month). Alternatively, patients suitable for prophylactic treatment may be human subjects without a history of HAE attacks but with one or more risk factors for HAE (e.g., family history, genetic defects in the C1-INH gene, etc.). Such prophylactic treatment may require a compound described herein as the sole active agent, or may require an additional anti-HAE agent, such as those described herein.

[0124] In certain embodiments, provided herein are methods for preventing or reducing edema in the eye of a subject (e.g., a human patient). In some examples, the human patient is a diabetic patient who has, is suspected of having, or is at risk for diabetic macular edema (DME). DME is a proliferative form of diabetic retinopathy characterized by swelling of the retinal layers, neovascularization, vascular leakage, and retinal thickening in diabetes due to leakage of fluid from blood vessels in the macula. To practice this method, an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt thereof, can be delivered to the eye of a subject in need of treatment. For example, the compounds of the present invention can be delivered by intraocular or intravitreal injection. The subject can be treated with a compound described herein either as the sole active agent or in combination with another treatment for DME. Non-limiting examples of treatments for DME include laser photocoagulation, steroids, drugs that target the VEGF pathway (e.g., Lucentis® (ranibizumab) or Eylea® (aflibercept)), and / or anti-PDGF drugs.

[0125] In certain embodiments, the methods disclosed herein include administering to a subject an effective amount of a compound of Formula (I)-(V), or a pharmaceutically acceptable salt thereof, or a composition thereof. In some embodiments, the effective amount is a therapeutically effective amount. In some embodiments, the effective amount is a prophylactically effective amount.

[0126] In certain embodiments, the subject to be treated is an animal. The animal may be of either sex and at any stage of development. In certain embodiments, the subject is a mammal. In certain embodiments, the subject to be treated is a human. In certain embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a companion animal, such as a dog or cat. In certain embodiments, the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a zoo animal. In other embodiments, the subject is a research animal, such as a rodent (e.g., mouse, rat), dog, pig, or non-human primate. In certain embodiments, the animal is a genetically engineered animal. In certain embodiments, the animal is a transgenic animal.

[0127] Certain methods described herein may include administering one or more additional pharmaceutical agents in combination with a compound described herein. The additional pharmaceutical agent(s) may be administered simultaneously with the compound of Formula (I)-(V) or at a different time than the compound of Formula (I)-(V). For example, the compound of Formula (I)-(V) and any additional pharmaceutical agent(s) may be on the same administration schedule or different administration schedules. All or a portion of the dose of the compound of Formula (I)-(V) may be administered before all or a portion of the dose of the additional pharmaceutical agent, after all or a portion of the dose of the additional pharmaceutical agent, within the administration schedule of the additional pharmaceutical agent, or a combination thereof. The timing of administration of the compound of Formula (I)-(V) and the additional pharmaceutical agent may vary depending on the additional pharmaceutical agent.

[0128] In certain embodiments, the additional pharmaceutical agent comprises an agent useful in the treatment of edema, e.g., HAE or DME. Examples of such agents are provided herein.

[0129] The following numbered embodiments are illustrative, but not limiting, of certain aspects of the present disclosure. 1. Formula (I): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur. A is 0 to 4 R A is substituted with a group, Each R A is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, B is 0 to 5 R B is substituted with a group, Each R B is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; L is selected from -QC(R)2-, -C(R)2Q-, -QC(Q)-, -C(Q)Q-, -C(R)2QC(O)-, and -C(O)QC(R)2-, where each Q is independently a monovalent or divalent group, where valency allows, selected from the group consisting of O, N(R), or (S); R 1 , R 2 , R 3 , and R 4 is hydrogen and C 1~6 are independently selected from aliphatic, R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two R groups on the same carbon or nitrogen atom are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; The compound or a pharmaceutically acceptable salt thereof, provided that the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0130] 2. The compound has the formula (IV): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen or nitrogen, and Cy A is 0 to 3 R A is substituted with a group, L is selected from -NC(O)- and -C(O)N-; R 6 , R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 7 is -F, -Cl, or -Br, W 4 is carbon or nitrogen, R 10 and R 11 are each optionally present and, if present, are selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 13 is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 2~6an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 14 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 3~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0131] 3. The compound has the formula (V): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 nitrogen atoms, and Cy A If contains three nitrogen atoms, Cy A teeth [ka] Instead, L is selected from -NC(O)- and -C(O)N-; R 6 , R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 7 is -F, -Cl, or -Br, R 10is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 11 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 13is -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R )2, or an optionally substituted group selected from phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- or 5- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 14 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 3~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, the compound of any one of the preceding embodiments, wherein two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0132] 4. The compound of any one of the preceding embodiments, wherein L is selected from -QC(R)2-, -C(R)2Q-, -C(Q)Q-, or -C(R)2QC(O)-, and Q is independently selected from O or N(R), a monovalent or divalent group, where valency allows.

[0133] 5. The compound of any one of the preceding embodiments, wherein L is -N(H)C(O)-.

[0134] 6. The compound of any one of the preceding embodiments, wherein L is -C(O)N(H)-. [ka] is selected from the group consisting of The compound of any one of the preceding embodiments, wherein # represents the point of attachment to CyA.

[0135] 7.L is the following: [ka] is selected from the group consisting of The compound of any one of the preceding embodiments, wherein # represents the point of attachment to CyA.

[0136] 8.L is, [ka] and The compound of any one of the preceding embodiments, wherein # represents the point of attachment to CyA.

[0137] 9.R 3 and R 4 The compound of any one of the preceding embodiments, wherein is hydrogen.

[0138] 10. The compound has the formula (II): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur. A is 0 to 4 R A is substituted with a group, Each R A is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, B is 0 to 5 R B is substituted with a group, Each R B is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 1 and R 2 is hydrogen and C 1~6 are independently selected from aliphatic, R 6 and R7 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two R groups on the same carbon or nitrogen atom are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; The compound of any one of the preceding embodiments, with the proviso that said compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0139] 11. Cy Ais a group other than pyridinediyl and the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0140] 12. Cy A is selected from 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy A However, 0 to 4 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0141] 13. Cy A is a 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy A However, 0 to 3 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0142] 14. Cy A is a 6-membered heteroarylene having one nitrogen atom, and Cy A However, 0 to 3 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0143] 15. Cy A but, [ka] is selected from either The compound of any one of the preceding embodiments, wherein * represents the point of attachment to L.

[0144] 16. Cy A is a 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy AHowever, 0 to 4 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0145] 17. Cy A is a 9-membered bicyclic heteroarylene having two nitrogen atoms, and Cy A However, 0 to 4 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0146] 18. Cy A However, 0 to 4 R A The compound of any one of the preceding embodiments, wherein the compound is pyrrolopyridinediyl substituted with a group.

[0147] 19. Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy A However, 0 to 2 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0148] 20. Cy A However, 0 to 3 R A Pyrrolediyl substituted with 0 to 2 R A pyrazolediyl substituted with a group, 0 to 1 R A triazolediyl substituted with a group, 0 to 1 R A Thiazoldiyl substituted with 0 to 2 R A Imidazolediyl substituted with a group, 0 to 1 R A Oxazoldiyl substituted with a group, 0 to 1 R A The compound of any one of the preceding embodiments, wherein the compound is selected from the group consisting of: isoxazolediyl substituted with a group, unsubstituted tetrazolediyl, unsubstituted oxadiazoldiyl, and unsubstituted thiadiazoldiyl.

[0149] 21. Cy A But the following: [ka] [ka] is selected from the group consisting of The compound of any one of the preceding embodiments, wherein * represents the point of attachment to L.

[0150] 22. Cy A The compound of any one of the preceding embodiments, wherein is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen or nitrogen.

[0151] 23. Cy A The compound of any one of the preceding embodiments, wherein is a 5-membered heteroarylene having 1 to 4 nitrogens.

[0152] 24. Cy A is a 5-membered heteroarylene having 1 to 4 nitrogens, and when CyA contains 3 nitrogens, it is not 1,2,4-triazolediyl.

[0153] 25. Cy A But the following: [ka] is selected from the group consisting of The compound of any one of the preceding embodiments, wherein * represents the point of attachment to L.

[0154] 26. The compound is represented by formula (III-a) to (III-d): [ka] [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Each R A is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, B is 0 to 5 R B is substituted with a group, Each R B is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 1 and R 2 is hydrogen and C 1~6 are independently selected from aliphatic, R 6 and R 7 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, the compound of any one of the preceding embodiments, wherein two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0155] 27. Cy B is selected from 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from phenyl, oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy B However, 0 to 5 R B The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0156] 28. Cy B is a 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy B However, 0 to 5 R B The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0157] 29. Cy B is a 10-membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy B However, 0 to 5 R B The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0158] 30. Cy B is a 10-membered bicyclic heteroaryl having one nitrogen atom, and Cy B However, 0 to 5 R B The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0159] 31. Cy BHowever, 0 to 5 R B A quinolonyl group substituted with a group and 0 to 5 R B ##STR00002## The compound of any one of the preceding embodiments, wherein the compound is selected from the group consisting of quinoxalinyl groups substituted with a group.

[0160] 32. Cy B But the following: [ka] The compound of any one of the preceding embodiments, selected from the group consisting of:

[0161] 33. Cy B is a 9-membered bicyclic heteroaryl having 1 to 5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy B However, 0 to 5 R B The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0162] 34. Cy B but, [ka] and During the ceremony, W 1 , W 2 , W 3 , and W 4 are independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, the compound of any one of the preceding embodiments, wherein two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0163] 35.W 4 The compound of any one of the preceding embodiments, wherein is carbon.

[0164] 36.W 4The compound of any one of the preceding embodiments, wherein is nitrogen.

[0165] 37.W 1 is nitrogen and W 2 , W 3 , and W 4 The compound of any one of the preceding embodiments, wherein is carbon.

[0166] 38.W 2 is nitrogen and W 1 , W 3 , and W 4 The compound of any one of the preceding embodiments, wherein is carbon.

[0167] 39. Nitrogen and W 1 and W 4 The compound of any one of the preceding embodiments, wherein is carbon.

[0168] 40.W 2 and W 4 is nitrogen and W 1 and W 3 The compound of any one of the preceding embodiments, wherein is carbon.

[0169] 41. Cy B However, 0 to 5 R B Imidazopyridinyl substituted with 0-5 R groups B pyrazolopyridinyl substituted with 0-4 R groups; B pyrrolopyridinyl substituted with 0 to 4 R groups; B triazolopyridinyl substituted with 0-4 R groups; B Imidazopyrimidinyl substituted with 0-4 R groups B imidazopyridazinyl substituted with 0 to 5 R groups B Indolizinyl substituted with a group, and 0 to 4 R B 3. The compound of any one of the preceding embodiments, wherein the compound is selected from the group consisting of: pyrazolopyrimidinyl substituted with a group.

[0170] 42. Cy B But the following: [ka] The compound of any one of the preceding embodiments, selected from the group consisting of:

[0171] 43. Cy B but, [ka] and During the ceremony, W 2 is selected from carbon, nitrogen, oxygen, and sulfur; W 1 , W 3 , and W 4 are independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14 are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of Each R is independently hydrogen, -CN, or C 1~6an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, the compound of any one of the preceding embodiments, wherein two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0172] 44. Cy B However, 0 to 5 R B Indolyl substituted with 0-5 R groups B benzofuranyl substituted with 0 to 4 R groups; B benzimidazolyl substituted with a group, and 0 to 4 R B 3. The compound of any one of the preceding embodiments, wherein the compound is selected from the group consisting of: thienopyridinyl substituted with a group.

[0173] 45. Cy B But the following: [ka] The compound of any one of the preceding embodiments, selected from the group consisting of:

[0174] 46.Each R A But C 1~6 The compound of any one of the preceding embodiments, wherein the optionally substituted group is independently selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0175] 47. Optionally substituted R A The substituents on the group are independently halogen, (CH2) 0~4 R°, -(CH2) 0~4 OR°; and -(CH2) 0~4 C(O)OR°, where each R° is independently hydrogen, C 1~6 The compound of any one of the preceding embodiments, which is an aliphatic or 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0176] 48.R A One example is halogen-substituted C 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0177] 49.R A One example is -(CH2) 0~4 C substituted with OR° 1~6 Aliphatic, R° is hydrogen or C 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0178] 50.R A One example is -(CH2) 0~4 C substituted with C(O)OR° 1~6 Aliphatic, R° is hydrogen or C 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0179] 51.R A One example of is C substituted with a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0180] 52.R A

[0023] In some embodiments, R is an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. A One example of is optionally substituted cyclopropyl. In some embodiments, R A One example is -(CH2) 0~4 C(O)OR° substituted cyclopropyl, where R° is hydrogen or C 1~6 It is aliphatic.

[0181] 53.R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -N(R)2, -OR, or C 1~6 an optionally substituted group selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and each R is independently hydrogen or C 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0182] 54.R 5 , R 8 , and R 9 The compound of any one of the preceding embodiments, wherein is hydrogen.

[0183] 55.R 6 The compound of any one of the preceding embodiments, wherein is selected from hydrogen or halogen.

[0184] 56.R 6 The compound of any one of the preceding embodiments, wherein is hydrogen.

[0185] 57.R 6 The compound of any one of the preceding embodiments, wherein is halogen.

[0186] 58.R 6 The compound of any one of the preceding embodiments, wherein is —F.

[0187] 59.R 6 The compound of any one of the preceding embodiments, wherein is —Cl.

[0188] 60.R 6 The compound of any one of the preceding embodiments, wherein is —Br.

[0189] 61.R 7 is halogen or optionally substituted C 1~6 The compound of any one of the preceding embodiments, wherein the compound is selected from aliphatic.

[0190] 62.R 7 The compound of any one of the preceding embodiments, wherein is halogen.

[0191] 63.R 7 The compound of any one of the preceding embodiments, wherein is —F.

[0192] 64.R 7 The compound of any one of the preceding embodiments, wherein is —Cl.

[0193] 65.R 7 The compound of any one of the preceding embodiments, wherein is —Br.

[0194] 66.R 7 is arbitrarily substituted C 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0195] 67.R 11 is optionally present and, if present, is selected from halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6The compound of any one of the preceding embodiments, wherein the optionally substituted group is selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0196] 68.R 13 is -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R )C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or aryl having 1-4 heteroatoms selected from aryl, oxygen, nitrogen, or sulfur; 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl; and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0197] 69.R 13 halogen, optionally substituted C 1~6 The compound of any one of the preceding embodiments, wherein the compound is selected from aliphatic, and optionally substituted 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl.

[0198] 70.R 13 The compound of any one of the preceding embodiments, wherein is halogen.

[0199] 71.R 13 is arbitrarily substituted C 1~6 The compound of any one of the preceding embodiments, wherein the compound is aliphatic.

[0200] 72.R 13 The compound of any one of the preceding embodiments, wherein is an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.

[0201] 73.R 13 The compound of any one of the preceding embodiments, wherein is an optionally substituted 3 or 5-7 membered saturated or partially unsaturated monocyclic carbocyclyl.

[0202] 74.R 13 The compound of any one of the preceding embodiments, wherein is optionally substituted cyclopropyl.

[0203] 75. The compound of any one of the preceding embodiments, wherein said compound is any of compounds I-1 to I-303, or a pharmaceutically acceptable salt thereof.

[0204] 76. A pharmaceutical composition comprising any of the foregoing compounds.

[0205] 77. The aforementioned pharmaceutical composition comprising any of the aforementioned compounds, further comprising a pharmaceutically acceptable excipient.

[0206] 78. The pharmaceutical composition according to any one of embodiments 76-77, wherein the composition is suitable for oral administration.

[0207] 79. The pharmaceutical composition according to any one of embodiments 76-77, wherein the composition is suitable for administration by injection.

[0208] 80. A method of treating a disease or disorder mediated by plasma kallikrein using a compound or composition according to any one of the preceding embodiments.

[0209] 81. The method of embodiment 80, wherein the disease or disorder is hereditary angioedema or diabetic macular edema.

[0210] 82. A method of treating hereditary angioedema or diabetic macular edema, comprising administering to a patient in need thereof a compound of any one of the preceding embodiments.

[0211] The following numbered embodiments are also illustrative of certain aspects of the present disclosure, but are not limiting. 83. Formula (I): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur. A is 0 to 4 R A is substituted with a group, Each R A is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy is selected from 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur, B is 0 to 5 R B is substituted with a group, Each R B is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, - N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; L is selected from -QC(R)2-, -C(R)2Q-, -QC(Q)-, -C(Q)Q-, -C(R)2QC(O)-, and -C(O)QC(R)2-, where each Q is independently a monovalent or divalent group, where valency allows, selected from the group consisting of O, N(R), or (S); R 1 , R 2 , R 3 , and R 4 is hydrogen and C 1~6 are independently selected from aliphatic, R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)-N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)C(O)N(R)2, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, -S(O)R, -S(O)2R, -S(O)N(R)2, -S(O)2N(R)2, or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two R groups on the same carbon or nitrogen atom are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; The compound or a pharmaceutically acceptable salt thereof, provided that the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0212] 84. The compound has the formula (II): [ka] or a pharmaceutically acceptable salt thereof.

[0213] 85. Cy A is a group other than pyridinediyl and the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

[0214] 86. Cy A is selected from 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, and 7-10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy A However, 0 to 4 R A The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0215] 87. Cy A However, 0 to 4 R A Pyrrolopyridinediyl substituted with 0-2 R A pyrazolediyl substituted with a group, 0 to 1 R Atriazolediyl substituted with a group, 0 to 1 R A Thiazoldiyl substituted with 0 to 2 R A Imidazolediyl substituted with a group, 0 to 1 R A Oxazoldiyl substituted with a group, 0 to 1 R A The compound of any one of the preceding embodiments, wherein the compound is selected from the group consisting of: isoxazolediyl substituted with a group, unsubstituted tetrazolediyl, unsubstituted oxadiazoldiyl, and unsubstituted thiadiazoldiyl.

[0216] 88.Cy A But the following: [ka] is selected from the group consisting of The compound of any one of the preceding embodiments, wherein * represents the point of attachment to L.

[0217] 89. The compound is selected from the group consisting of: [ka] or a pharmaceutically acceptable salt thereof.

[0218] 90.Cy B is a 7-10 membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur; and Cy B However, 0 to 5 R B The compound of any one of the preceding embodiments, wherein the compound is substituted with a group.

[0219] 91. Cy B but, [ka] and During the ceremony, W 1, W 2 , W 3 , and W 4 are independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14 are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, the compound of any one of the preceding embodiments, wherein two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.

[0220] 92. Cy B However, 0 to 5 R B Imidazopyridinyl substituted with 0-5 R groups B pyrazolopyridinyl substituted with 0-4 R groups; B pyrrolopyridinyl substituted with 0 to 4 R groups; B triazolopyridinyl substituted with 0-4 R groups; B Imidazopyrimidinyl substituted with 0-4 R groups B imidazopyridazinyl substituted with 0 to 5 R groups B Indolizinyl substituted with a group, and 0 to 4 R B 3. The compound of any one of the preceding embodiments, wherein the compound is selected from the group consisting of: pyrazolopyrimidinyl substituted with a group.

[0221] 93. Cy B But the following: [ka] The compound of any one of the preceding embodiments, selected from the group consisting of:

[0222] 94. Cy B but, [ka] and During the ceremony, W 2 is selected from carbon, nitrogen, oxygen, and sulfur; W 1 , W 3 , and W4 are independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14 are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O)R, -C(O)N(R), -NO, -N(R)-N(R), -N(R), -N(R)C(O)R, -N(R)C(O)R, -N(R)C(O)N(R), -N(R)S(O)R, -OR, -OC(O)R, -OC(O)N(R), -SR, -S(O)R, -S(O)R, -S(O)N(R), -S(O)N(R), or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of Each R is independently hydrogen, -CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Alternatively, two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur. Compounds of any one of embodiments 83-90.

[0223] 95.Cy B However, 0 to 5 R B Indolyl substituted with 0-5 R groups B benzofuranyl substituted with 0 to 4 R groups; B pyrazolopyrimidinyl substituted with 0-4 R groups; B benzimidazolyl substituted with a group, and 0 to 4 R B 95. The compound according to any one of embodiments 83-90 and 94, wherein the compound is selected from the group consisting of thienopyridinyl substituted with a group.

[0224] 96. Cy B But the following: [ka] The compound of any one of embodiments 83-90 and 94-95, selected from the group consisting of:

[0225] 97.Cy B However, 0 to 5 R B The compound of any one of embodiments 83-90, wherein the quinolonyl group is substituted with a group.

[0226] 98.Cy B but, [ka] The compound of any one of embodiments 83-90 and 97, wherein

[0227] 99. The compound according to any one of the preceding embodiments, wherein L is —N(H)C(O)—, or L is —C(O)N(H)—.

[0228] 100.R 6 The compound of any one of the preceding embodiments, wherein is halogen.

[0229] 101.R 13 halogen, optionally substituted C 1~6Compounds according to embodiments 91 or 94, wherein the carbocyclyl is selected from aliphatic, and optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.

[0230] 102.R 13 The compound of embodiment 91 or 94, wherein is optionally substituted cyclopropyl.

[0231] 103. A pharmaceutical composition comprising any of the foregoing compounds.

[0232] 104. The pharmaceutical composition according to embodiment 103, further comprising a pharmaceutically acceptable excipient.

[0233] 105. The pharmaceutical composition according to any one of embodiments 103-104, wherein the composition is suitable for oral administration.

[0234] 106. The pharmaceutical composition according to any one of embodiments 103-104, wherein the composition is suitable for administration by injection.

[0235] 107. A method for treating a disease or disorder mediated by plasma kallikrein using a compound according to any one of embodiments 83-102 or a composition according to any one of embodiments 103-106.

[0236] 108. The method of embodiment 27, wherein the disease or disorder is hereditary angioedema or diabetic macular edema.

[0237] 109. A method of treating hereditary angioedema or diabetic macular edema, comprising administering to a patient in need thereof a compound according to any one of embodiments 83-102 or a composition according to any one of embodiments 103-106. [Example]

[0238] Example 1 Scheme 1 [ka] Synthesis of methyl 1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxylate. A mixture of 3-chloro-6-(chloromethyl)quinoline (200 mg, 0.95 mmol), methyl 1H-pyrazole-4-carboxylate (1.2 g, 0.95 mmol), and CsCO (930 mg, 2.85 mmol) in MeCN (5 mL) was stirred at 70 °C for 1 hour. Water was added, and the mixture was extracted with EtOAc. The combined organic layer was concentrated and purified by silica gel column (EA / PE=1 / 10) to give methyl 1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxylate (200 mg, yield: 78%) as a white solid. ESI-MS [M+H] + : 302.1.

[0239] Synthesis of 1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxylic acid. A mixture of methyl 1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxylate (200 mg, 0.66 mmol) and LiOH (158 mg, 6.6 mmol) in THF (10 mL) and HO (5 mL) was stirred at 100 °C overnight. Water was added, and the pH of the mixture was adjusted to 4-5 by adding 1 M HCl solution. The mixture was then extracted with EtOAc (20 mL × 3), and the combined organic layers were concentrated to give 1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxylic acid (150 mg, yield: 72%) as a white solid, which was used in the next step without further purification. ESI-MS [M+H] + : 288.0.

[0240] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxamide (I-1). A mixture of 1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxylic acid (50 mg, 0.17 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (37 mg, 0.17 mmol), HATU (98 mg, 0.06 mmol), and DIPEA (66 mg, 0.51 mmol) in DMF (2 mL) was stirred at room temperature overnight. Water (10 mL) was added, extracted with EtOAc (20 mL x 3), and the combined organic layers were concentrated and purified by preparative HPLC to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxamide (17.3 mg, yield: 20%) as a white solid. ESI-MS [M+H] + : 451.1. Purity: 99.49%. 1 H NMR (400 MHz, DMSO): δ 8.88 (d,J = 2.2 Hz, 1H), 8.64-8.58 (m, 2H), 8.36-8.31 (m, 3H), 8.03 (d, J = 8.7 Hz, 1H),7.94 (s, 1H), 7.80 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 8.7 Hz, 1H), 6.67 (dd, J =7.4, 1.8 Hz, 1H), 5.56 (s, 2H), 4.57 (d, J = 5.4 Hz, 2H).

[0241] Example 2 Scheme 2 [ka] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide. To a mixture of (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (2.5 g, 11.52 mmol), 1H-pyrazole-4-carboxylic acid (920 mg, 8.23 ​​mmol), and HATU (3.9 g, 10.29 mmol) in DMF (300 mL) was added DIPEA (7.3 mL, 41.14 mmol). The resulting reaction mixture was stirred at room temperature for 14 hours. The reaction was then concentrated to remove most of the DMF, and the residue was poured into HO (150 mL), resulting in the precipitation of a brown solid. The precipitate was filtered and the filter cake was triturated with DCM and dried to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, which was used in the next step without further purification (2 g, yield: 88%). ESI-MS [M+H] + : 276.2.

[0242] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-2). A mixture of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (2 g, 7.27 mmol), 2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (1.96 g, 9.45 mmol), and CsCO (7.1 g, 21.81 mmol) in DMF (50 mL) was stirred at 50 °C for 14 h. HO (200 mL) was added, and the mixture was extracted with EtOAc (300 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (DCM / MeOH=10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide as a white solid (1.5 g, yield: 46%). LCMS m / z: 446.1 [M+H] + , t R =1.040 min, purity: 98.6% (214nm), 97.4% (254nm). 1 HNMR (400 MHz, DMSO): δ 8.58 (t, J = 5.7 Hz, 1H), 8.32-8.29 (m, 3H), 8.20 (s, 1H),7.85 (s, 1H), 7.78 (s, 1H), 7.71 (s, 1H), 7.39 (d, J = 9.3 Hz, 1H), 7.00-6.98 (m,1H), 6.64 (dd, J = 7.5, 2.0 Hz, 1H), 5.38 (s, 2H), 4.55 (d, J = 5.7 Hz, 2H), 1.91(ddd, J = 13.5, 8.4, 5.1 Hz, 1H), 0.99-0.87 (m, 2H), 0.77-0.61 (m, 2H).

[0243] Example 3 Scheme 3 [ka] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide (I-3). To a solution of 2-((3-chloroquinolin-6-yl)methyl)isonicotinic acid (60 mg, 0.20 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (44 mg, 0.24 mmol), and HATU (115 mg, 0.30 mmol) in DMF (8 mL) was added DIPEA (77 mg, 0.60 mmol). The resulting reaction was stirred at room temperature for 12 hours. HO (20 mL) was added and the mixture was extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH=10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide (20 mg, yield: 22%) as a white solid. ESI-MS [M+H] + : 462.0. Purity: 98.3%. 1 H NMR (400 MHz, DMSO): δ 9.27-9.24(m, 1H), 8.84-8.81 (m, 1H), 8.62 (d, J = 5.0 Hz, 1H), 8.51 (s, 1H), 8.38-8.26 (m,2H), 7.97 (d, J = 8.6 Hz, 1H), 7.90-7.69 (m, 4H), 7.62 (d, J = 4.7 Hz, 1H), 6.66(d, J = 7.4 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.35 (s, 2H).

[0244] Example 4 Scheme 4 [ka] Synthesis of tert-butyl ((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamate. A mixture of (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (300 mg, 1.65 mmol), BocO (537 mg, 2.4 mmol), and DIPEA (1.06 g, 8.25 mmol) in DCM (40 mL) was stirred at room temperature for 12 hours. The reaction was quenched with HO (50 mL) and extracted with DCM (50 mL × 2). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (PE / EA=1 / 1) to give tert-butyl ((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamate (210 mg, yield: 45%) as a yellow solid. ESI-MS [M+H] + : 282.2.

[0245] Synthesis of tert-butyl ((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)carbamate. In a sealed tube, a mixture of tert-butyl ((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamate (210 mg, 0.75 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (188 mg, 1.5 mmol), Pd(PPh) (87 mg, 0.075 mmol), and KCO (310 mg, 2.25 mmol) in dioxane / HO (10 mL / 1 mL) was stirred at 100 °C for 12 h. HO (30 mL) was added to the reaction mixture, which was then extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (EA / PE=1 / 1) to give tert-butyl ((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)carbamate (150 mg, yield: 77%) as a pale yellow solid. ESI-MS [M+H] + : 262.3.

[0246] Synthesis of (7-methylimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride. To a solution of tert-butyl ((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)carbamate (150 mg, 0.57 mmol) in MeOH (3 mL) was added HCl (4 M solution in MeOH, 3 mL). The resulting reaction was stirred at room temperature for 2 hours. The reaction was concentrated under reduced pressure to give (7-methylimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (95 mg, yield: 85%). ESI-MS [M+H] + : 162.2.

[0247] Synthesis of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (I-4). To a solution of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (136 mg, 0.48 mmol), (7-methylimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (95 mg, 0.48 mmol), and HATU (238 mg, 0.63 mmol) in DMF (15 mL) was added DIPEA (310 mg, 2.4 mmol). The resulting reaction was stirred at room temperature for 12 hours. HO (25 mL) was added to the reaction mixture and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (21 mg, yield: 10%) as a white solid. ESI-MS [M+H] + : 426.2. Purity: 96.4%. 1H NMR (400 MHz, DMSO): δ 8.47 (s,1H), 8.39-8.04 (m, 5H), 7.86 (s, 1H), 7.71 (s, 1H), 7.40-7.35 (m, 2H), 6.99 (d,J = 9.1 Hz, 1H), 6.45 (d, J = 7.0 Hz, 1H), 5.38 (s, 2H), 4.54 (d, J = 4.5 Hz, 2H),2.20 (s, 3H), 1.95-1.88 (m, 1H), 0.93-0.90 (m, 2H), 0.68-0.63 (m, 2H).

[0248] Example 5 Scheme 5 [ka] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-5). To a solution of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (154 mg, 0.54 mmol), (7-bromoimidazo[1,5-a]pyridin-1-yl)methanamine (120 mg, 0.54 mmol), and HATU (310 mg, 0.82 mmol) in DMF (4 mL) was added DIPEA (210 mg, 1.63 mmol). The resulting reaction was stirred at room temperature for 12 hours. H2O (20 mL) was added and extracted with EtOAc (25 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (24 mg, yield: 9%) as a white solid. ESI-MS [M+H] + : 490.1. Purity: 98.24%. 1H NMR (400 MHz, DMSO): δ 8.57 (t,J = 8.0 Hz, 1H), 8.32 (d, J = 4.2 Hz, 2H), 8.24 (d, J = 7.5 Hz, 1H), 8.20 (s, 1H),7.95 (s, 1H), 7.85 (s, 1H), 7.71 (s, 1H), 7.39 (d, J = 9.4 Hz, 1H), 6.99 (d, J =9.3 Hz, 1H), 6.72 (dd, J = 7.4, 1.8 Hz, 1H), 5.38 (s, 2H), 4.54 (d, J = 5.7 Hz,2H),1.98-1.87 (m, 1H), 1.01-0.76 (m, 2H), 0.76-0.55 (m, 2H).

[0249] Example 6 Scheme 6 [ka] Synthesis of tert-butyl ((mesitylsulfonyl)oxy)carbamate. To a mixture of tert-butyl hydroxycarbamate (3 g, 22.5 mmol) and 2,4,6-trimethylbenzenesulfonyl chloride (4.9 g, 22.5 mmol) in MTBE (100 mL) was added EtN (2.43 g, 24.0 mmol) at 0°C. The mixture was stirred at 0°C for 2 hours. The reaction mixture was filtered and washed with MTBE. The filtrate was concentrated to give tert-butyl ((mesitylsulfonyl)oxy)carbamate (7.1 g, yield: 100%) as a pale yellow solid. ESI-MS [M+Na] + : 338.1.

[0250] Synthesis of O-(mesitylsulfonyl)hydroxylamine. A mixture of tert-butyl ((mesitylsulfonyl)oxy)carbamate (5.9 g, 18.71 mmol) in TFA (20 mL) was stirred at 0 °C for 2 h. The reaction mixture was poured into HO (150 mL) and stirred for 30 min. The precipitate was collected and dried to give O-(mesitylsulfonyl)hydroxylamine (2.2 g, 55% yield) as a white solid, which was used in the next step without further purification. ESI-MS [M+H] + : 216.2.

[0251] Synthesis of 5-cyclopropylpyridin-2-amine. A mixture of 5-bromopyridin-2-amine (4 g, 23.12 mmol), cyclopropylboronic acid (2.98 g, 34.68 mmol), Pd(OAc) (130 mg, 0.578 mmol), tricyclohexylphosphine (324 mg, 1.16 mmol), and KPO (17.18 g, 80.92 mmol) in toluene (100 mL) and HO (10 mL) was stirred at 90 °C for 16 h. The reaction mixture was filtered and rinsed with EtOAc. The combined filtrate was washed with HO (150 mL × 1) and brine (150 mL × 1), dried over NaSO, concentrated, and purified by silica gel chromatography (EA / PE = 1 / 1) to give 5-cyclopropylpyridin-2-amine (2.76 g, 89% yield) as a yellow solid. ESI-MS [M+H] + : 135.2.

[0252] Synthesis of 5-cyclopropyl-2-iminopyridin-1(2H)-amine 2,4,6-trimethylbenzenesulfonate. To a stirred solution of O-(mesitylsulfonyl)hydroxylamine (2.2 g, 10.22 mmol) in DCM (40 mL) was added 5-cyclopropylpyridin-2-amine (1.37 g, 10.22 mmol) in four portions at 0°C. The mixture was stirred at 0°C for 10 minutes, warmed to room temperature, and stirred for 1 hour. The reaction mixture was concentrated and dried under reduced pressure to give 5-cyclopropyl-2-iminopyridin-1(2H)-amine 2,4,6-trimethylbenzenesulfonate (3.57 g, 100% yield) as a light brown syrup. ESI-MS [M+H] + : 150.2.

[0253] Synthesis of ethyl 6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate. To a stirred solution of 5-cyclopropyl-2-iminopyridin-1(2H)-amine 2,4,6-trimethylbenzenesulfonate (3.57 g, 10.22 mmol) in pyridine (30 mL), 2-chloro-2-oxoethyl acetate (2.79 g, 20.44 mmol) was added at room temperature. The mixture was stirred at 100° C. for 16 hours. The reaction mixture was concentrated. The residue was dissolved in EtOAc (100 mL), washed with HO (100 mL × 1), brine (100 mL × 1), dried over NaSO, concentrated, and purified by silica gel chromatography (EA / PE = 1 / 1) to give ethyl 6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate (1.1 g, yield: 47%) as a yellow solid. ESI-MS [M+H] + : 232.1.

[0254] Synthesis of (6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methanol. To a stirred solution of ethyl 6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate (300 mg, 1.30 mmol) in MeOH (10 mL) was added NaBH (246 mg, 6.5 mmol) portionwise at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was then quenched with aqueous NH Cl. MeOH was removed, and the reaction was diluted with HO (50 mL) and extracted with EtOAc (30 mL × 3). The combined organic components were washed with brine (80 mL × 1), dried over Na2SO4, concentrated, and purified by silica gel chromatography (EA / MeOH = 10 / 1) to give (6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methanol (210 mg, yield: 85%) as a yellow solid. ESI-MS [M+H] + : 190.2.

[0255] Synthesis of 2-(chloromethyl)-6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridine. To a stirred solution of (6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methanol (110 mg, 0.58 mmol) in DCM (5 mL) was added SOCl (690 mg, 5.8 mmol) at 0 °C. The mixture was stirred at room temperature for 1 h. The reaction mixture was then concentrated, and the residue was dissolved in EtOAc (60 mL), washed with NaHCO (50 mL × 1), brine (50 mL × 1), dried over NaSO, and concentrated to give 2-(chloromethyl)-6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridine (115 mg, 96% yield) as a yellow solid, which was used in the next step without further purification. ESI-MS [M+H] + : 208.1.

[0256] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-6). A mixture of 2-(chloromethyl)-6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridine (15.8 mg, 0.0762 mmol), N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (20 mg, 0.0725 mmol), and CsCO (35 mg, 0.109 mmol) in DMF (3 mL) was stirred at room temperature for 2 hours. The reaction mixture was poured into HO (30 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine (60 mL × 3), dried over NaSO, concentrated, and purified by preparative TLC (DCM / MeOH = 5 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (15 mg, yield: 47%) as a yellow solid. ESI-MS [M+H] + : 447.1. Purity: 99%. 1 H NMR (400 MHz, DMSO): δ 8.73 (s, 1H),8.62 (t, J = 5.7 Hz, 1H), 8.31 (d, J = 7.9 Hz, 3H), 7.86 (s, 1H), 7.80 (d, J = 0.9Hz, 1H), 7.66 (d, J = 9.2 Hz, 1H), 7.42 (dd, J = 9.2, 1.7 Hz, 1H), 6.65 (dd, J =7.5, 2.1 Hz, 1H), 5.56 (s, 2H), 4.57 (d, J = 5.7 Hz, 2H), 2.03 (m, 1H), 0.97 (m,2H), 0.78 (m, 2H).

[0257] Example 7 Scheme 7 [ka] Synthesis of 6-chloro-2-(chloromethyl)-5-methylimidazo[1,2-a]pyridine. To a solution of (6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methanol (60 mg, 0.31 mmol) in DCM (10 mL) was added SOCl (1 mL) at room temperature. The resulting reaction was stirred at 45 °C for 2 hours. The solution was evaporated to give 6-chloro-2-(chloromethyl)-5-methylimidazo[1,2-a]pyridine (50 mg, crude) as a pale yellow solid, which was used in the next step without further purification. ESI-MS [M+H] + : 215.2.

[0258] Synthesis of 1-((6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (I-7). To a solution of 6-chloro-2-(chloromethyl)-5-methylimidazo[1,2-a]pyridine (50 mg, 0.23 mmol) in DMF (10 mL) was added N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (41 mg, 0.15 mmol) and CsCO (146 mg, 0.45 mmol) at room temperature. The resulting reaction was stirred at room temperature for 12 hours. HO (30 mL) was added to the reaction mixture, which was then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give 1-((6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (40 mg, yield: 58%) as a white solid. ESI-MS [M+H] + : 454.1. Purity: 100%. 1H NMR (400 MHz, DMSO): δ 8.59 (t, J= 5.5 Hz, 1H), 8.31-8.29 (m, 2H), 8.23 ​​(s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.78(s, 1H), 7.47 (d, J = 9.5 Hz, 1H), 7.34 (d, J = 9.5 Hz, 1H), 6.65 (d, J = 7.4 Hz,1H), 5.44 (s, 2H), 4.55 (d, J = 5.6 Hz, 2H), 2.66 (s, 3H).

[0259] Example 8 Scheme 8 [ka] Synthesis of (7-isopropylimidazo[1,2-a]pyridin-2-yl)methanol. To a solution of ethyl 7-isopropylimidazo[1,2-a]pyridine-2-carboxylate (200 mg, 0.86 mmol) in THF (4 mL) was added LiAlH (65.5 mg, 1.72 mmol). The resulting reaction was stirred at room temperature for 4 hours. The reaction was quenched with saturated NaSO (aq), filtered, concentrated, and purified by silica gel column (DCM / MeOH=10 / 1) to give (7-isopropylimidazo[1,2-a]pyridin-2-yl)methanol (130 mg, 80%) as a brown liquid. ESI-MS [M+H] + : 191.2.

[0260] Synthesis of 2-(chloromethyl)-7-isopropylimidazo[1,2-a]pyridine. To a solution of (7-isopropylimidazo[1,2-a]pyridin-2-yl)methanol (190 mg, 1 mmol) in DCM (10 mL) was added SOCl (2 mL). The resulting reaction was stirred at 50 °C for 2 h. The reaction was concentrated under reduced pressure to give 2-(chloromethyl)-7-isopropylimidazo[1,2-a]pyridine (220 mg crude), which was used in the next step without further purification. ESI-MS [M+H] + : 209.2.

[0261] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-isopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-8). A mixture of 2-(chloromethyl)-7-isopropylimidazo[1,2-a]pyridine (46 mg, 0.22 mmol), N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (38 mg, 0.14 mmol), and CsCO (142 mg, 0.44 mmol) in DMF (8 mL) was stirred at 80 °C for 12 h. HO (15 mL) was added to the reaction mixture, which was then extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH=10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-isopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (15 mg, 24%) as a white solid. ESI-MS [M+H] + : 448.2. Purity: 100%. 1 H NMR (400 MHz, DMSO): δ 8.58 (t, J= 5.6 Hz, 1H), 8.32 (m, 3H), 8.20 (s, 1H), 7.85 (s, 1H), 7.77 (m, 2H), 7.43 (d,J = 9.3 Hz, 1H), 7.21 (d, J = 9.3 Hz, 1H), 6.64 (dd, J = 7.4, 1.9 Hz, 1H), 5.39(s, 2H), 4.55 (d, J = 5.7 Hz, 2H), 2.96-2.80 (m, 1H), 1.22 (d, J = 6.9 Hz, 6H).

[0262] Example 9 Scheme 9 [ka] Synthesis of (5-methylimidazo[1,2-a]pyridin-2-yl)methanol. A solution of 5-chloro-6-methylpyridin-2-amine (568 mg, 4.0 mmol) and ethyl 3-bromo-2-oxopropanoate (1.2 g, 6.0 mmol) in anhydrous EtOH (10 mL) was stirred at 80° C. for 8 hours. The mixture was concentrated and purified by silica gel chromatography (DCM / MeOH=20 / 1) to give ethyl 6-chloro-5-methylimidazo[1,2-a]pyridine-2-carboxylate (800 mg, yield: 84.0%) as a yellow solid. ESI-MS [M+H] + : 239.1.

[0263] Synthesis of (5-methylimidazo[1,2-a]pyridin-2-yl)methanol. To a solution of ethyl 6-chloro-5-methylimidazo[1,2-a]pyridine-2-carboxylate (240 mg, 1.0 mmol) in anhydrous THF (10 mL) was added LiAlH (115 mg, 3.0 mmol) slowly at 0 °C. The reaction mixture was stirred at room temperature for 5 hours and then quenched with NaSO·10H O. The mixture was filtered, and the filtrate was washed with EtOAc (20 mL). The filtrate was concentrated to give (5-methylimidazo[1,2-a]pyridin-2-yl)methanol (150 mg, 92% yield) as a yellow oil, which was used in the next step without further purification. ESI-MS [M+H] + : 163.1.

[0264] Synthesis of 2-(chloromethyl)-5-methylimidazo[1,2-a]pyridine. To a solution of (5-methylimidazo[1,2-a]pyridin-2-yl)methanol (150 mg, 0.925 mmol) in anhydrous DCM (5 mL) was added SOCl2 (0.5 mL) at room temperature. The mixture was stirred at 40 °C for 1 hour. The mixture was concentrated to give crude 2-(chloromethyl)-5-methylimidazo[1,2-a]pyridine (140 mg, yield: 94.6%) as a yellow solid. ESI-MS [M+H] + : 181.2.

[0265] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-9). A mixture of 2-(chloromethyl)-5-methylimidazo[1,2-a]pyridine (30 mg, 0.16 mmol), N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (30 mg, 0.11 mmol), and CsCO (110 mg, 0.33 mmol) in DMF (3 mL) was stirred at room temperature for 16 hours. Water (30 mL) was added, and the reaction was extracted with EtOAc (30 mL × 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH=10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (11.5 mg, yield: 25%) as a pale yellow solid. ESI-MS [M+H] + : 420.1. Purity: 97.4%. 1 H NMR (400 MHz, DMSO): δ 8.58 (t,J = 5.4 Hz, 1H), 8.31-8.29 (m, 2H), 8.23 ​​(s, 1H), 7.86 (s, 1H), 7.78 (s, 2H), 7.41(d, J = 9.1 Hz, 1H), 7.24-7.20 (m, 1H), 6.78 (d, J = 6.8 Hz, 1H), 6.64 (dd, J =7.5, 1.9 Hz, 1H), 5.43 (s, 2H), 4.55 (d, J = 5.7 Hz, 2H), 2.56 (s, 3H).

[0266] Example 10 Scheme 10 [ka] Synthesis of ethyl 1-((6-(prop-1-en-2-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A mixture of ethyl 1-((6-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (600 mg, 1.97 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (662 mg, 3.94 mmol), Pd(dppf)Cl (160 mg, 0.2 mmol), and KPO (1.25 g, 5.91 mmol) in dioxane / HO (20 mL / 2 mL) was stirred at 115 °C for 24 hours. HO (50 mL) was added to the reaction mixture and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC (chromatography column: Gemini-C18 150 × 21.2 mm, 5 μm, mobile phase: acetonitrile-HO (0.1% FA), gradient: 10-20) to give ethyl 1-((6-(prop-1-en-2-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (450 mg, yield: 73%) as a white solid. ESI-MS [M+H] + : 311.2.

[0267] Synthesis of ethyl 1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. To a solution of Zn(Et) (1.9 mL, 1 M solution in hexanes, 1.9 mmol) in DCM (4 mL) was added TFA (220 mg in 1 mL of DCM, 1.9 mmol) using an addition funnel at 0 °C. The resulting reaction was stirred at 0 °C for 20 min. Then, a solution of CHI (509 mg in 2 mL of DCM, 1.9 mmol) was added at 0 °C. After stirring for an additional 20 min, a solution of 1-((6-(prop-1-en-2-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (50 mg, 0.16 mmol) in DCM (1 mL) was added. The resulting reaction was warmed to room temperature and stirred for 16 hours. The reaction was quenched with HO (20 mL) and extracted with DCM (25 mL x 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 15 / 1) to give ethyl 1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (17 mg, yield: 33%) as a yellow solid. ESI-MS [M+H] + : 325.1.

[0268] Synthesis of 1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. A mixture of ethyl 1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (17 mg, 0.052 mmol) and LiOH (4 mg, 0.16 mmol) in THF / MeOH / HO (2 mL / 2 mL / 1 mL) was stirred at 70° C. for 2 hours. The pH of the reaction was adjusted to 4, HO (5 mL) was added, and the mixture was extracted with EtOAc (20 mL × 3). The combined organic layers were then concentrated under reduced pressure to give 1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (15 mg, yield: 98%) as a yellow oil, which was used in the next step without further purification. ESI-MS [M+H] + : 297.1.

[0269] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-10). To a solution of 1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (15 mg, 0.05 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (13 g, 0.06 mmol), and HATU (28 mg, 0.075 mmol) in DMF (3 mL) was added DIPEA (32 mg, 0.25 mmol). The resulting reaction was stirred at room temperature for 12 hours. HO (15 mL) was added to the reaction mixture, which was then extracted with EtOAc (25 mL x 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (7.5 mg, yield: 33%) as a white solid. ESI-MS [M+H] + : 460.2. Purity: 93.5%. 1 H NMR (400 MHz, MeOD): δ 8.27-8.25(m, 2H), 8.16 (d, J = 7.5 Hz, 1H), 8.12 (s, 1H), 7.91 (s, 1H), 7.73-7.72 (m, 2H),7.40 (d, J = 9.4 Hz, 1H), 7.26 (d, J = 9.4 Hz, 1H), 6.62 (d, J = 7.3 Hz, 1H), 5.44(s, 2H), 4.68 (s, 2H), 1.41 (s, 3H), 0.90-0.87 (m, 2H), 0.78-0.76 (m, 2H).

[0270] Example 11 Scheme 11 [ka] Synthesis of 6-chloro-2-(chloromethyl)imidazo[1,2-b]pyridazine. A solution of 6-chloropyridazin-3-amine (5 g, 39 mmol) and 1,3-dichloropropan-2-one (20 g, 156 mmol) in EtOH (50 mL) was stirred at 90 °C for 4 h. The reaction mixture was then diluted with HO (100 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were dried over NaSO, concentrated, and purified by column chromatography (PE / EA = 5 / 1) to give the desired product, 6-chloro-2-(chloromethyl)imidazo[1,2-b]pyridazine (2.6 g, yield: 33%) as a yellow solid. ESI-MS [M+H] + : 202.2.

[0271] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-11). A solution of 6-chloro-2-(chloromethyl)imidazo[1,2-b]pyridazine (50 mg, 0.25 mmol), N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (66 mg, 0.24 mmol), and CsCO (160 mg, 0.5 mmol) in DMF (3 mL) was stirred at room temperature for 2 hours. The reaction mixture was then diluted with HO (30 mL) and extracted with EtOAc (30 mL × 3). The combined organic layers were dried over NaSO, concentrated, and purified by column chromatography (CHCl / MeOH=10 / 1) to give the desired compound, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide (29.5 mg, yield: 27%) as a white solid. ESI-MS [M+H] + : 441.1. Purity: 98%. 1H NMR (400 MHz, DMSO): δ 8.58 (s, 1H),8.31 (s, 3H), 8.25 (s, 1H), 8.17 (d, J = 9.3 Hz, 1H), 7.86 (s, 1H),7.78 (s, 1H),7.38 (d, J = 9.5 Hz, 1H), 6.65 (d, J = 7.1 Hz, 1H), 5.47 (s, 2H), 4.56 (d, J = 5.0Hz, 2H).

[0272] Example 12 Scheme 12 [ka] Synthesis of 2-(chloromethyl)-7-cyclopropylimidazo[1,2-a]pyridine. To a solution of (7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methanol (126 mg, 0.67 mmol) in DCM (10 mL) was added SOCl (2 mL). The resulting reaction was stirred at 45 °C for 4 hours. The reaction was concentrated under reduced pressure to give 2-(chloromethyl)-7-cyclopropylimidazo[1,2-a]pyridine (150 mg crude), which was used in the next step without further purification. ESI-MS [M+H] + : 207.2.

[0273] Synthesis of ethyl 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A mixture of 2-(chloromethyl)-7-cyclopropylimidazo[1,2-a]pyridine (0.15 g crude from the previous step), ethyl 1H-pyrazole-4-carboxylate (126 mg, 0.9 mmol), and CsCO (1.17 g, 3.6 mmol) in DMF (8 mL) was stirred at 80 °C for 12 h. HO (15 mL) was added to the reaction, which was then extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH=10 / 1) to give ethyl 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (100 mg, 36%) as a yellow solid. ESI-MS [M+H] + : 311.2.

[0274] Synthesis of 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. A mixture of ethyl 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (600 mg, 1.94 mmol) and LiOH (270 mg, 11.6 mmol) in THF / EtOH / HO (6 mL / 6 mL / 4 mL) was stirred at 80° C. for 2 hours. The pH of the reaction was adjusted to approximately 5, and a yellow solid precipitated. The mixture was filtered, and the solid was dried to give 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (550 mg, 100% yield) as a brown solid. ESI-MS [M+H] + : 283.1.

[0275] 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-(( 7 -Methoxyimidazo[1, 5 -a]pyridine- 1Synthesis of 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-12). To a solution of 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (23 mg, 0.08 mmol), (7-methoxyimidazo[1,5-a]pyridin-1-yl)methanamine (14 mg, 0.08 mmol), and HATU (45.6 mg, 0.12 mmol) in DMF (3 mL) was added DIPEA (30 mg, 0.24 mmol). The resulting reaction was stirred at room temperature overnight. HO (20 mL) was added to the reaction, which was then extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH=10 / 1) to give 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-(( 7 -Methoxyimidazo[1, 5 -a]pyridine- 1 (-yl)methyl)-1H-pyrazole-4-carboxamide (30 mg, yield: 85%) was obtained. ESI-MS [M+H] + :442.1. Purity: 98.3%. 1 H NMR (400 MHz, MeOD): δ 8.22 (s,1H), 8.15(s, 1H), 8.12(s, 1H), 8.06 (d, J = 7.6 Hz, 1H), 7.94 (s, 1H), 7.73 (s,1H), 7.41 (d, J = 9.4 Hz,1H), 7.14 (d, J = 9.4 Hz, 1H), 6.90 (s, 1H), 6.41 (dd,J = 7.6, 2.2 Hz, 1H), 5.46(s, 2H), 4.69 (s, 2H), 3.81 (s, 3H), 2.05-1.83(m, 1H),1.07-0.92(m, 2H), 0.86-0.63(m, 2H).

[0276] Example 13 Scheme 13 [ka] Synthesis of ethyl 6-cyclopropyl-5-methylimidazo[1,2-a]pyridine-2-carboxylate. A mixture of 5-cyclopropyl-6-methylpyridin-2-amine (1.3 g, 8.78 mmol) and ethyl 3-bromo-2-oxopropanoate (3.5 g, 17.57 mmol) in EtOH (30 mL) was stirred at 90° C. for 16 hours. The mixture was concentrated and purified by silica gel chromatography (DCM / MeOH=20 / 1) to give ethyl 6-cyclopropyl-5-methylimidazo[1,2-a]pyridine-2-carboxylate (150 mg, yield: 7%) as a yellow solid. ESI-MS [M+H] + : 245.1.

[0277] Synthesis of (6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methanol. To a solution of ethyl 6-cyclopropyl-5-methylimidazo[1,2-a]pyridine-2-carboxylate (110 mg, 0.45 mmol) in anhydrous THF (5 mL) was added LiAlH (50 mg, 1.12 mmol) slowly at 0 °C. The mixture was stirred at room temperature for 1 hour, and then quenched with NaSO·10H O. The mixture was filtered, and the filtrate was washed with EtOAc (20 mL). The filtrate was concentrated and purified by preparative TLC (DCM / MeOH=15 / 1) to give (6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methanol (50 mg, yield: 55%) as a yellow solid. ESI-MS [M+H] + : 203.1.

[0278] Synthesis of 2-(chloromethyl)-6-cyclopropyl-5-methylimidazo[1,2-a]pyridine. To a solution of (6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methanol (50 mg, 0.25 mmol) in anhydrous DCM (2.5 mL) was added SOCl (0.5 mL) at room temperature. The mixture was stirred at 40 °C for 1 hour. The mixture was concentrated to give 2-(chloromethyl)-6-cyclopropyl-5-methylimidazo[1,2-a]pyridine (50 mg, yield: 90.9%) as a yellow oil, which was used in the next step without further purification. ESI-MS [M+H] + : 221.2.

[0279] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-13). A mixture of 2-(chloromethyl)-6-cyclopropyl-5-methylimidazo[1,2-a]pyridine (25 mg, 0.11 mmol), N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (30 mg, 0.11 mmol), and CsCO (110 mg, 0.33 mmol) in DMF (3 mL) was stirred at 50 °C for 2 h. Water (20 mL) was added, and the mixture was extracted with EtOAc (20 mL × 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH=10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (17 mg, yield: 33.7%) as a pale yellow solid. ESI-MS [M+H] + : 460.2. Purity: 99.5%. 1H NMR (400 MHz, DMSO): δ 8.57 (s,1H), 8.30 (d, J = 7.1 Hz, 2H), 8.20 (s, 1H), 7.85 (s, 1H), 7.77 (s, 2H), 7.33 (d,J = 9.6 Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 6.64 (d, J = 7.3 Hz, 1H), 5.40 (s, 2H),4.54 (d, J = 5.1 Hz, 2H), 2.64 (s, 3H), 2.02 (s, 1H), 0.94 (d, J = 8.2 Hz, 2H),0.64 (s, 2H).

[0280] Example 14 Scheme 14 [ka] Synthesis of ethyl 1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A mixture of 2-(chloromethyl)-6-cyclopropyl-5-methylimidazo[1,2-a]pyridine (65 mg, 0.30 mmol), ethyl 1H-pyrazole-4-carboxylate (45 mg, 0.32 mmol), and CsCO (245 mg, 0.75 mmol) in DMF (5 mL) was stirred at 50° C. for 2 hours. Water (20 mL) was added, and the mixture was extracted with EtOAc (20 mL×3). The combined organic layer was concentrated to give ethyl 1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (65 mg, yield: 67%) as a yellow solid. ESI-MS [M+H] + : 325.1.

[0281] Synthesis of 1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. A solution of ethyl 1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (65 mg, 0.2 mmol) and LiOH·HO (25 mg, 0.6 mmol) in THF / MeOH / HO (1 mL / 1 mL / 0.5 mL) was stirred at 80 °C for 1 h. The pH of the mixture was adjusted to 4 by adding 1 M HCl solution. Water (10 mL) was added, and the reaction was extracted with EtOAc (20 mL × 3). The combined organic layers were concentrated to give 1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (59 mg, yield: 99.7%) as a yellow oil, which was used directly in the next step without further purification. ESI-MS [M+H] + : 297.1.

[0282] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-14). A mixture of 1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (59 mg, 0.2 mmol), (7-bromoimidazo[1,5-a]pyridin-1-yl)methanamine (70 mg, 0.25 mmol), HATU (120 mg, 0.3 mmol), and DIPEA (0.1 mL, 0.6 mmol) in DMF (4 mL) was stirred at room temperature for 2 hours. Water (20 mL) was added, and the reaction mixture was extracted with EtOAc (30 mL x 3). The organic layer was concentrated and purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (42.2 mg, yield: 41.9%) as a white solid. ESI-MS [M+H] +: 504.1. Purity: 93.5%. 1 H NMR (400 MHz, DMSO): δ 8.57 (t,J = 5.7 Hz, 1H), 8.31 (s, 1H), 8.27-8.17 (m, 2H), 7.94 (s, 1H), 7.85 (s, 1H), 7.77(s, 1H), 7.33 (d, J = 9.3 Hz, 1H), 6.97 (d, J = 9.3 Hz, 1H), 6.71 (dd, J = 7.4,1.9 Hz, 1H), 5.41 (s, 2H), 4.54 (d, J = 5.7 Hz, 2H), 2.64 (s, 3H), 2.01-1.98 (m,1H), 0.94 (dd, J = 8.4, 1.7 Hz, 2H), 0.74-0.58 (m, 2H).

[0283] Example 15 Scheme 15 [ka] Synthesis of 6-chloro-2-(chloromethyl)imidazo[1,2-b]pyridazine. A solution of 6-chloropyridazin-3-amine (20.0 g, 155.0 mmol) and 1,3-dichloropropan-2-one (49.2 g, 387.5 mmol) in EtOH (200 mL) was stirred at 80 °C for 4 h. The reaction mixture was then concentrated, diluted with HO (300 mL × 3), and extracted with EtOAc (500 mL × 3). The combined organic layers were dried over NaSO, concentrated, and purified by column chromatography (DCM:MeOH = 10:1) to give the desired product, 6-chloro-2-(chloromethyl)imidazo[1,2-b]pyridazine (17.0 g, 54% yield) as a yellow solid. ESI-MS [M+H] + : 202.1.

[0284] Synthesis of ethyl 1-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A solution of 6-chloro-2-(chloromethyl)imidazo[1,2-b]pyridazine (10.0 g, 49.5 mmol), ethyl 1H-pyrazole-4-carboxylate (6.2 g, 44.5 mmol), and CsCO (48.4 g, 148.5 mmol) in DMF (200 mL) was stirred at room temperature for 2 hours. Most of the DMF was concentrated, and the residue was diluted with HO (300 mL) and extracted with EtOAc (500 mL × 3). The combined organic layers were dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc:PE=2:1) ​​to give the desired compound, ethyl 1-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylate (10.0 g, yield: 65%) as a yellow solid. ESI-MS [M+H] + : 306.1.

[0285] Synthesis of methyl 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A solution of ethyl 1-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylate (10.0 g, 32 mmol), cyclopropylboronic acid (4.2 g, 49 mmol), Pd(OAc) (718.4 mg, 3.2 mmol), SPhos (1.3 g, 3.2 mmol), and KPO (21.0 g, 96 mmol) in Tol / HO (100 mL / 10 mL) was stirred at room temperature for 2 hours. The reaction mixture was then diluted with HO (100 mL) and extracted with EtOAc (300 mL × 3). The combined organic layers were dried over Na2SO4, concentrated, and purified by column chromatography (EtOAc:PE=2:1) ​​to give the desired compound, ethyl 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylate (9.8 g, yield: 100%) as a white solid. ESI-MS [M+H] + : 312.2.

[0286] Synthesis of 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. A solution of ethyl 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylate (9.8 g, 32.0 mmol) and LiOH (1.5 g, 64.0 mmol) in THF / EtOH / HO (80 mL / 80 mL / 80 mL) was stirred at 80° C. for 2 hours. The reaction mixture was then concentrated and diluted with HO (50 mL). The pH of the solution was adjusted to 5 by adding 1 M HCl solution. A solid precipitated and was filtered to give the desired compound, 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (9.5 g, yield: 104.6%), as a white solid. ESI-MS [M+H] + : 284.1.

[0287] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-15). A solution of 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (9.5 g, 33.5 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (9.5 g, 43.5 mmol), EDCI (7.7 g, 40.2 mmol), HOBT (5.4 g, 40.2 mmol), and TEA (10.1 g, 13.9 mL, 100.5 mmol) in anhydrous DCM (800 mL) was stirred overnight at room temperature. The reaction mixture was then diluted with HO (500 mL × 3) and extracted with DCM (1 L × 3). The combined organic layers were dried over NaSO, concentrated, and purified by column chromatography (DCM:MeOH=10:1) to give the desired compound N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide (6.1 g, yield: 40.9%) as a white solid. ESI-MS [M+H] + : 447.1. Purity: 99.05%. 1 H NMR (400 MHz, DMSO): δ 8.58-8.55(t, J = 5.7 Hz, 1H), 8.30-8.28 (m, J = 7.5, 0.6 Hz, 2H), 8.21 (s, 1H), 8.07 (s,1H), 7.91 (d, J = 9.5 Hz, 1H), 7.84 (s, 1H), 7.77-7.76 (m, 1H), 7.08 (d, J = 9.5Hz, 1H), 6.63 (dd, J = 7.5, 2.1 Hz, 1H), 5.40 (s, 2H), 4.54 (d, J = 5.7 Hz, 2H),2.50-2.14 (m, J = 9.0, 4.1 Hz, 1H), 1.07-1.03 (m, J = 6.0, 4.1 Hz, 2H), 0.97-0.93(m, 2H).

[0288] Example 16 Scheme 16 [ka] Synthesis of 5-cyclopropyl-4-methylpyridin-2-amine. To a solution of 5-bromo-4-methylpyridin-2-amine (2 g, 10.7 mmol) in toluene / HO (50 mL / 5 mL) was added cyclopropylboronic acid (1.36 g, 16.0 mmol), Pd(OAc) (240 mg, 1.07 mmol), SPhos (439 mg, 1.07 mmol), and KPO (6.8 g, 32.1 mmol). The reaction mixture was stirred under nitrogen at 95 °C for 12 hours, then diluted with DCM (200 mL), washed with HO and brine, and concentrated to give a crude residue, which was purified by silica gel chromatography (PE / EtOAc = 1 / 1) to give 5-cyclopropyl-4-methylpyridin-2-amine as a yellow solid (4 g, 90% yield). ESI-MS [M+H] + : 149.2.

[0289] Synthesis of 2-(chloromethyl)-6-cyclopropyl-7-methylimidazo[1,2-a]pyridine. To a solution of 5-cyclopropyl-4-methylpyridin-2-amine (200 mg, 1.35 mmol) in DMF (10 mL) was added 1,3-dichloropropan-2-one (514 mg, 4.05 mmol) at room temperature. The resulting reaction mixture was stirred at 85° C. for 2 hours. The solution was quenched with HO (30 mL), adjusted to pH 8 by adding saturated NaHCO solution, and then extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (PE / EtOAc = 1 / 1) to give 2-(chloromethyl)-6-cyclopropyl-7-methylimidazo[1,2-a]pyridine (150 mg, yield: 51%) as a pale yellow oil. ESI-MS [M+H] + : 221.2.

[0290] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-17). To a solution of 2-(chloromethyl)-6-cyclopropyl-7-methylimidazo[1,2-a]pyridine (55 mg, 0.25 mmol) in DMF (4 mL) was added N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (45 mg, 0.16 mmol) and CsCO (156 mg, 0.48 mmol) at room temperature. The resulting reaction was stirred at room temperature for 12 hours. HO (20 mL) was added to the reaction mixture and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (20 mg, yield: 27%) as a white solid. ESI-MS [M+H] + : 460.1. 1 H NMR (400 MHz, DMSO): δ 8.58 (t, J = 5.7 Hz,1H), 8.35-8.27 (m, 2H), 8.23 ​​(s, 1H), 8.19 (s, 1H), 7.86 (s, 1H), 7.79-7.74 (m,1H), 7.66 (s, 1H), 7.30 (s, 1H), 6.66-6.63 (m, 1H), 5.38 (s, 2H), 4.55 (d, J = 5.7Hz, 2H), 2.42 (s, 3H), 1.88-1.82 (m, 1H), 0.94-0.84 (m, 2H), 0.62-0.54 (m, 2H).

[0291] Example 17 Scheme 17 [ka] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-17). To a solution of 2-(chloromethyl)-6-cyclopropyl-7-methylimidazo[1,2-a]pyridine (50 mg, 0.23 mmol) in DMF (4 mL) was added N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (48 mg, 0.15 mmol) and CsCO (147 mg, 0.45 mmol) at room temperature. The resulting reaction was stirred at room temperature for 12 hours. The reaction was quenched with HO (20 mL) and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (22 mg, yield: 29%) as a white solid. ESI-MS [M+H] + : 506.1. Purity: 91.6%. 1 H NMR (400 MHz, DMSO): δ 8.58-8.55(m, 1H), 8.31 (s, 1H), 8.24 (d, J = 7.4 Hz, 1H), 8.19-8.17 (m, 2H), 7.95 (s, 1H),7.84 (s, 1H), 7.62 (s, 1H), 7.26 (s, 1H), 6.73-6.70 (m, 1H), 5.35 (s, 2H), 4.54(d, J = 5.7 Hz, 2H), 2.40 (s, 3H), 1.85-1.81 (m, 1H), 0.89-0.87 (m, 2H), 0.58-0.56(m, 2H).

[0292] Example 18 Scheme 18 [ka] Synthesis of 2-(chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine. A solution of 5-(trifluoromethyl)pyridin-2-amine (500 mg, 3.1 mmol) and 1,3-dichloropropan-2-one (1.2 g, 9.3 mmol) in DMF (15 mL) was stirred at 95 °C for 13 hours. The reaction was quenched with aqueous NaHCO (20 mL) and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (PE / EA = 1 / 2) to give 2-(chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine (350 mg, yield: 48%) as a yellow solid. ESI-MS [M+H] + : 235.2.

[0293] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-18). A mixture of 2-(chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine (200 mg, 0.85 mmol), N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (234 mg, 0.85 mmol), and CsCO (831 mg, 2.55 mmol) in DMF (10 mL) was stirred at 55 °C for 2 h. HO (30 mL) was added to the reaction mixture and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (25 mg, yield: 6.2%) as a white solid. ESI-MS [M+H] + : 474.2. Purity: 99.7%. 1H NMR (400 MHz, MeOD): δ 8.99 (s,1H), 8.27 (s, 1H), 8.19-8.17 (m, 2H), 7.93 (s, 2H), 7.75 (s, 1H), 7.66 (d, J = 9.5Hz, 1H), 7.50 (dd, J = 9.5, 1.5 Hz, 1H), 6.63 (dd, J = 7.5, 1.9 Hz, 1H), 5.52 (s,2H), 4.70 (s, 2H).

[0294] Example 19 Scheme 19 [ka] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-19). A mixture of 2-(chloromethyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine (200 mg, 0.85 mmol), N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (271 mg, 0.85 mmol), and CsCO (831 mg, 2.55 mmol) in DMF (10 mL) was stirred at 55 °C for 2 h. HO (30 mL) was added to the reaction mixture and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (40 mg, yield: 9%) as a white solid. ESI-MS [M+H] + : 518.0. Purity: 94.14%. 1H NMR (400 MHz, MeOD): δ 8.99 (s,1H), 8.27 (s, 1H), 8.19 (s, 1H), 8.11 (d, J = 7.4 Hz, 1H), 7.94 (s, 3H), 7.66 (d,J = 9.5 Hz, 1H), 7.50 (d, J = 9.5 Hz, 1H), 6.75-6.67 (m, 1H), 5.52 (s, 2H), 4.70(s, 2H).

[0295] Example 20 Scheme 20 [ka] Synthesis of 5-cyclopropyl-4-fluoropyridin-2-amine. A mixture of 5-bromo-4-fluoropyridin-2-amine (1 g, 5.2 mmol), cyclopropylboronic acid (675 mg, 7.9 mmol), Pd(AcO) (116 mg, 0.52 mmol), PCy (280 mg, 1 mmol), and KPO (3.3 g, 15.6 mmol) in toluene / HO (50 mL / 5 mL) was stirred in a sealed tube under N at 105 °C for 12 hours. The reaction was concentrated to give the crude product, which was purified by silica gel chromatography (PE / EA = 1 / 1) to give 5-cyclopropyl-4-fluoropyridin-2-amine (500 mg, 64% yield) as a white solid. ESI-MS [M+H] + : 153.2.

[0296] Synthesis of 2-(chloromethyl)-6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridine. A mixture of 5-cyclopropyl-4-fluoropyridin-2-amine (500 mg, 3.3 mmol) and 1,3-dichloropropan-2-one (1.25 g, 9.9 mmol) in DMF (30 mL) was stirred at 95 °C for 13 hours. The pH of the reaction was adjusted to 9 by adding aqueous NaHCO3 solution, and then extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (PE / EA = 3 / 1) to give 2-(chloromethyl)-6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridine (150 mg, yield: 20%) as a yellow solid. ESI-MS [M+H] + : 225.1.

[0297] Synthesis of ethyl 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A mixture of 2-(chloromethyl)-6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridine (150 mg, 0.67 mmol), ethyl 1H-pyrazole-4-carboxylate (103 mg, 0.74 mmol), and CsCO (655 mg, 2.01 mmol) in DMF (10 mL) was stirred at 55 °C for 2 h. HO (30 mL) was added to the reaction mixture, which was then extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (DCM / MeOH=20 / 1) to give ethyl 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (100 mg, yield: 45%) as a yellow solid. ESI-MS [M+H] + : 329.2.

[0298] Synthesis of 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. To a solution of ethyl 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (100 mg, 0.31 mmol) in THF / EtOH / HO (4 mL / 4 mL / 2 mL) was added LiOH (22 mg, 0.91 mmol). The resulting reaction was stirred at 80° C. for 1.5 hours. Most of the solvent was removed. The pH of the residue was adjusted to approximately 5, resulting in the precipitation of a yellow solid. The mixture was filtered and the solid was dried to give 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (75 mg, yield: 81%) as a yellow solid. ESI-MS [M+H] + : 301.1.

[0299] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-20). To a solution of 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (35 mg, 0.12 mmol), (7-bromoimidazo[1,5-a]pyridin-1-yl)methanamine (35 mg, 0.15 mmol), and HATU (68 mg, 0.18 mmol) in DMF (5 mL) was added DIPEA (77 mg, 0.6 mmol). The resulting reaction was stirred at room temperature for 2 hours. Water (30 mL) was added and extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (19 mg, yield: 32%). ESI-MS [M+H] +: 508.1. Purity: 90.5%. 1 H NMR (400 MHz, MeOD): δ 8.26 (s,1H), 8.18 (d, J = 7.1 Hz, 1H), 8.13 (s, 1H), 8.10 (d, J = 7.4 Hz, 1H), 7.92 (s,1H), 7.91 (s, 1H), 7.67 (s, 1H), 7.12 (d, J = 10.3 Hz, 1H), 6.72 (d, J = 7.4 Hz,1H), 5.41 (s, 2H), 4.68 (s, 2H), 2.04-1.87 (m, 1H), 1.02-0.97 (m, 2H), 0.76-0.72(m, 2H).

[0300] Example 21 Scheme 21 [ka] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-21). To a solution of 1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (35 mg, 0.12 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (28 mg, 0.15 mmol), and HATU (68 mg, 0.18 mmol) in DMF (5 mL) was added DIPEA (77 mg, 0.6 mmol). The resulting reaction was stirred at room temperature for 2 hours. Water (30 mL) was added and extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (20 mg, yield: 32%). ESI-MS [M+H]+ : 464.1. Purity: 94.8%. 1 H NMR (400 MHz, MeOD): δ 8.25 (s,1H), 8.19-8.12 (m, 3H), 7.90 (s, 1H), 7.73 (s, 1H), 7.68 (s, 1H), 7.13 (d, J = 10.3Hz, 2H), 6.62 (dd, J = 7.5, 1.9 Hz, 1H), 5.41 (s, 2H), 4.68 (s, 2H), 1.37 (dd, J= 6.7, 3.3 Hz, 1H), 1.02-0.97 (m, 2H), 0.75-0.71 (m, 2H).

[0301] Example 22 Scheme 22 [ka] Synthesis of 6-cyclopropylpyridin-2-amine. To a solution of 2-amino-6-bromopyridine (1.0 g, 5.75 mmol) in toluene / HO (15 mL / 3 mL) was added cyclopropylboronic acid (1.98 g, 23 mmol), palladium diacetate (134 mg, 0.63 mmol), 2-dicyclohexylphosphino-2',6-dimethoxybiphenyl (240 mg, 0.6 mmol), and potassium phosphate (4.24 g, 20.12 mmol). The resulting mixture was stirred at 90 °C for 16 h. The reaction mixture was diluted with HO (20 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give 6-cyclopropylpyridin-2-amine (621 mg, 81% yield). ESI-MS [M+H] + : 135.2.

[0302] Synthesis of 2-(chloromethyl)-5-cyclopropylimidazo[1,2-a]pyridine. To a solution of 5-cyclopropylpyrimidin-2-amine (600 mg, 4.5 mmol) in N,N-dimethylformamide (2 mL) was added 1,3-dichloropropan-2-one (2.2 g, 18.0 mmol). The resulting mixture was stirred at 80 °C for 2.5 h. The reaction mixture was quenched with HO (50 mL) and extracted with ethyl acetate (3 × 30 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give 2-(chloromethyl)-5-cyclopropylimidazo[1,2-a]pyridine (300 mg, 33% yield). ESI-MS [M+H] + : 207.1.

[0303] Synthesis of ethyl 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. To a solution of 2-(chloromethyl)-5-cyclopropylimidazo[1,2-a]pyridine (150 mg, 0.73 mmol) in N,N-dimethylformamide (2 mL) was added cesium carbonate (949 mg, 2.92 mmol) and ethyl 1H-pyrazole-4-carboxylate (102 mg, 0.73 mmol). The resulting mixture was stirred at room temperature for 3 hours. Water (50 mL) was added and extracted with ethyl acetate (3×30 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give ethyl 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (220 mg, yield: 80%). ESI-MS [M+H] + : 311.2.

[0304] Synthesis of 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. To a solution of ethyl 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (210 mg, 0.68 mmol) in a THF / EtOH / HO (3 mL / 3 mL / 1.5 mL) mixed solvent was added lithium hydroxide (82 mg, 3.39 mmol). The resulting mixture was stirred at 80 °C for 1.5 h. Water (50 mL) was added, and the pH of the mixture was adjusted to 4-5 by adding HCl solution. The mixture was then extracted with DCM (3 × 30 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated to give 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (140 mg, yield: 60%), which was used in the next step without further purification. ESI-MS [M+H] + : 283.1.

[0305] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-22). To a solution of 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (67 mg, 0.21 mmol) in anhydrous DMF (3 mL) was added HATU (116 mg, 0.305 mmol), DIPEA (16 mg, 0.125 mmol), and (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (44 mg, 0.24 mmol) at room temperature. The reaction was stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative HPLC to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (36 mg, yield: 30%) as a white solid. ESI-MS [M+H] + : 446.2. Purity: 98.74. 1 H NMR (400 MHz, DMSO): δ 8.59 (t,J = 5.6 Hz, 1H), 8.34-8.26 (m, 2H), 8.25 (s, 1H), 8.02 (s, 1H), 7.86 (s, 1H), 7.78(s, 1H), 7.41 (d, J = 9.0 Hz, 1H), 7.24-7.14 (m, 1H), 6.72-6.61 (m, 2H), 5.45 (s,2H), 4.55 (d, J = 5.8 Hz, 2H), 2.18 (s, 1H), 1.13-1.1.02 (m, 2H), 0.83-0.74 (m,, 2H).

[0306] Example 23 Scheme 23 [ka] Synthesis of 6-chloro-5-cyclopropylpyridin-2-amine. A mixture of 5-bromo-6-chloropyridin-2-amine (3 g, 14 mmol), cyclopropylboronic acid (2.4 g, 28 mmol), Pd(OAc) (313.6 mg, 1.4 mmol), tricyclohexylphosphine (784 mg, 2.8 mmol), and KPO (5.9 g, 28 mmol) in dioxane / HO (20 mL / 20 mL) was stirred in a sealed tube under N at 100 °C for 16 h. The reaction was concentrated to give the crude product, which was purified by silica gel chromatography (PE / EA = 5 / 1) to give 6-chloro-5-cyclopropylpyridin-2-amine (2.4 g, 98% yield) as a white solid. ESI-MS [M+H] + : 169.2.

[0307] Synthesis of 5-chloro-2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine. A mixture of 6-chloro-5-cyclopropylpyridin-2-amine (2.4 g, 14.2 mmol) and 1,3-dichloropropan-2-one (7.16 g, 56.8 mmol) in ethanol (30 mL) was stirred at 78 °C for 16 hours. The mixture was quenched with saturated NaHCO (50 mL) and extracted with DCM (100 mL × 3). The combined organic layer was concentrated and purified by flash column silica gel chromatography (DCM / MeOH = 15 / 1) to give 5-chloro-2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (1.8 g, 53% yield) as a yellow solid. ESI-MS [M+H] + : 241.1.

[0308] Synthesis of ethyl 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. To a solution of 5-chloro-2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (800 mg, 3.33 mmol) in anhydrous DMF (10 mL) was added ethyl 1H-pyrazole-4-carboxylate (512.4 mg, 3.66 mmol) and CsCO (3.25 g, 10 mmol). The reaction mixture was then stirred at 55 °C under a N atmosphere for 16 h. The mixture was cooled to room temperature, diluted with HO (20 mL), and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (DCM / MeOH=10 / 1) to give ethyl 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (870 mg, yield: 76%) as a white solid. ESI-MS [M+H] + : 345.2.

[0309] Synthesis of 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. To a solution of ethyl 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (300 mg, 0.87 mmol) in THF (5 mL) and HO (5 mL) was added LiOH·HO (110 mg, 2.62 mmol), and the reaction mixture was stirred at 50° C. for 16 h. The solvent was removed, and the pH of the residue was adjusted to approximately 5 by adding 1 M HCl solution, resulting in the precipitation of a yellow solid. The mixture was filtered and the solid was dried to give 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (175 mg, yield: 64%) as a white solid. ESI-MS [M+H] + : 317.1.

[0310] Synthesis of 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (I-23). ​​To a solution of 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (100 mg, 0.32 mmol) in anhydrous DMF (3 mL) was added (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (69.4 mg, 0.32 mmol), HATU (182 mg, 0.48 mmol), and DIPEA (124 mg, 0.96 mmol), and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with HO (20 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH = 10 / 1) to give 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (15 mg, yield: 9.8%) as a white solid. ESI-MS [M+H] + : 480.1. Purity: 90.37%. 1 H NMR (400 MHz, DMSO-d6): δ 8.58(t, J = 5.5 Hz, 1H), 8.30 (d, J = 6.8 Hz, 2H), 8.24 (s, 1H), 7.92 (s, 1H), 7.86(s, 1H), 7.78 (s, 1H), 7.50 (d, J = 9.3 Hz, 1H), 6.98 (d, J = 9.3 Hz, 1H), 6.64(d, J = 7.5, 1.9 Hz, 1H), 5.46 (d, J = 9.6 Hz, 2H), 4.55 (d, J = 5.6 Hz,2H), 2.19-2.06(m, 1H), 1.03(m, 2H), 0.78 (m, 2H).

[0311] Example 24 Scheme 24 [ka] Synthesis of 4-chloro-5-cyclopropylpyridin-2-amine. A mixture of 5-bromo-4-chloropyridin-2-amine (3.24 g, 15.6 mmol), cyclopropylboronic acid (2.01 g, 23.4 mmol), Pd(OAc) (350 mg, 1.56 mmol), KPO (6.62 g, 31.2 mmol), and PCy (875 mg, 3.12 mmol) in toluene (40 mL) and HO (5 mL) was stirred at 80 °C overnight. Water (100 mL) was added, and the mixture was extracted with EtOAc (100 mL × 3). The combined organic components were concentrated and purified by silica gel chromatography (EA / PE = 2:3 to 10:1) to give 4-chloro-5-cyclopropylpyridin-2-amine (1.89 g, 18.7% yield) as a yellow solid. ESI-MS [M+H] + : 169.1.

[0312] Synthesis of 7-chloro-2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine. To a solution of 4-chloro-5-cyclopropylpyridin-2-amine (1.2 g, 7.1 mmol) in DMF (20 mL) was added 1,3-dichloropropan-2-one (1.8 g, 14.2 mmol) at room temperature. The mixture was stirred at 100 °C for 2 h, then HO (50 mL) was added and extracted with EtOAc (100 mL × 3). The combined organic layer was concentrated and purified by silica gel chromatography (EA / PE = 1:10 to 3:7) to give 7-chloro-2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (674 mg, 38% yield) as a yellow solid. ESI-MS [M+H] + : 241.1.

[0313] Synthesis of ethyl 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. A mixture of 7-chloro-2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (480 mg, 2.0 mmol), ethyl 1H-pyrazole-4-carboxylate (689 mg, 4.92 mmol), and CsCO (2.4 g, 7.38 mmol) in DMF (10 mL) was stirred at 60° C. for 3 hours. Water (50 mL) was added, and the mixture was extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give the crude product, which was purified by silica gel chromatography (EA / PE=7:3 to 10:1) to give ethyl 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (390 mg, yield: 57%) as a white solid. ESI-MS [M+H] + : 345.1.

[0314] Synthesis of 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. To a solution of ethyl 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (200 mg, 0.58 mmol) in ethanol / THF / HO (3 mL / 3 mL / 1.5 mL) was added LiOH·HO (97 mg, 2.32 mmol). The reaction mixture was stirred at 65 °C for 3 hours. The mixture was then concentrated and diluted with HO (20 mL). The pH of the aqueous layer was adjusted to 4 by adding 1 M HCl solution and extracted with EtOAc (50 mL × 3). The combined organic layers were concentrated to give crude 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (230 mg) as a white solid, which was used in the next step without further purification. ESI-MS [M+H] + : 317.1.

[0315] Synthesis of 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (I-24). A mixture of crude 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (230 mg, 0.73 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (65.1 mg, 0.3 mmol), HATU (278 mg, 0.73 mmol), and DIPEA (375 mg, 2.9 mmol) in DMF (5 mL) was stirred at room temperature for 3 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were concentrated and purified by preparative TLC (DCM:MeOH = 8:1) to give 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (11.1 mg, yield: 7.7%) as a white solid. ESI-MS [M+H] + : 480.0. Purity: 98.15%. 1 H NMR (400 MHz, DMSO): δ 8.58 (t,J = 5.3 Hz, 1H), 8.40 (s, 1H), 8.31-8.30 (m, 2H), 8.20 (s, 1H), 7.86 (s, 1H), 7.78(s, 1H), 7.72 (s, 1H), 7.68 (s, 1H), 6.65 (dd, J = 7.4, 1.8 Hz, 1H), 5.40 (s, 2H),4.55 (d, J = 5.6 Hz, 2H), 1.98-1.94 (m, 1H), 0.95-0.94 (m, 2H), 0.66-0.65 (m, 2H).

[0316] Example 25 Scheme 25 [ka] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-25). A mixture of crude 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (230 mg, 0.73 mmol), (7-bromoimidazo[1,5-a]pyridin-1-yl)methanamine (67.8 mg, 0.3 mmol), HATU (278 mg, 0.73 mmol), and DIPEA (375 mg, 2.9 mmol) in DMF (5 mL) was stirred at room temperature for 3 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were concentrated and purified by preparative TLC (DCM:MeOH = 8:1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (31.5 mg, yield: 20%) as a white solid. ESI-MS [M+H] + : 524.0. Purity: 97%. 1 H NMR (400 MHz, DMSO): δ 8.58-8.57 (m,1H), 8.39 (s, 1H), 8.31 (s, 1H), 8.23-8.20 (m, 2H), 7.94 (s, 1H), 7.85 (s, 1H),7.69 (d, J = 13.8 Hz, 2H), 6.72-6.71 (m, 1H), 5.39 (s, 2H), 4.54 (s, 2H), 1.95-1.93(m, 1H), 0.94-0.93 (m, 2H), 0.65-0.64 (m, 2H).

[0317] Example 26 Scheme 26 [ka] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5,6-dimethylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (I-26). To a solution of 1-((5,6-dimethylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (54 mg, 0.2 mmol) in anhydrous DMF (3 mL) was added HATU (114 mg, 0.3 mmol), DIPEA (129 mg, 1.0 mmol), and (7-bromoimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (52.4 mg, 0.2 mmol) at room temperature. The reaction was stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative HPLC to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5,6-dimethylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (9.7 mg, yield: 10.2%). ESI-MS [M+H] + : 478.1. Purity: 90.33%. 1 H NMR (400 MHz, DMSO): δ 8.58 (t,J = 5.6 Hz, 1H), 8.31 (s, 1H), 8.28-8.18 (m, 2H), 7.95 (s, 1H), 7.85 (s, 1H), 7.76(s, 1H), 7.33 (d, J = 9.1 Hz, 1H), 7.14 (d, J = 9.2 Hz, 1H), 6.76-6.67 (m, 1H),5.40 (s, 2H), 4.54 (d, J = 5.7 Hz, 2H), 2.49 (s, 3H), 2.29 (s, 3H).

[0318] Example 27 Scheme 27 [ka] Synthesis of 5-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine. To a solution of 6-bromopyridin-2-amine (800 mg, 4.6 mmol) in N,N-dimethylformamide (5 mL) was added 1,3-dichloropropan-2-one (3.05 g, 24.0 mmol). The resulting mixture was stirred at 90 °C for 2.5 h. The reaction mixture was diluted with HO (50 mL) and extracted with ethyl acetate (3 × 30 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give 5-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine (600 mg, 53% yield). ESI-MS [M+H] + : 245.0.

[0319] Synthesis of ethyl 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate. To a solution of 5-bromo-2-(chloromethyl)imidazo[1,2-a]pyridine (200 mg, 0.82 mmol) in N,N-dimethylformamide (3 mL) was added cesium carbonate (1.1 g, 3.28 mmol) and ethyl 1H-pyrazole-4-carboxylate (115 mg, 0.82 mmol). The resulting mixture was stirred at room temperature for 2 hours, then diluted with HO (50 mL) and extracted with ethyl acetate (3 × 30 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography to give ethyl 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (236 mg, yield: 83%). ESI-MS [M+H] + : 349.0.

[0320] Synthesis of 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid. To a solution of ethyl 1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylate (236 mg, 0.68 mmol) in a mixture of THF / HO (3 mL / 3 mL) was added lithium hydroxide (82 mg, 3.4 mmol). The resulting mixture was stirred at 80 °C for 2 h. THF was evaporated, and the pH of the HO phase was adjusted to 5 by adding 1 M HCl solution. The resulting solid precipitate was filtered to give 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (131 mg, yield: 60%), which was used in the next step without further purification. ESI-MS [M+H] + : 321.0.

[0321] Synthesis of 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (I-27). To a solution of 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxylic acid (65 mg, 0.20 mmol) in anhydrous DMF (3 mL) was added HATU (116 mg, 0.305 mmol), DIPEA (131 mg, 1.02 mmol), and (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (44 mg, 0.20 mmol) at room temperature. The reaction was stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative HPLC to give 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (41 mg, yield: 37%). ESI-MS [M+H] + : 484.0. Purity: 100%. 1H NMR (400 MHz, DMSO): δ 8.60 (t, J= 5.6 Hz, 1H), 8.39 (s, 1H), 8.32 (d, J = 7.5 Hz, 1H), 8.26 (s, 1H), 7.97 (s, 1H),7.88 (s, 1H), 7.81 (s, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.33 (d, J = 7.2 Hz, 1H),7.31-7.21 (m, J = 8.7, 7.4 Hz, 1H), 6.72-6.63 (m, 1H), 5.48 (s, 2H), 4.57 (d, J= 5.7 Hz, 2H).

[0322] Example 28 Scheme 28 [ka] Synthesis of 6-bromo-2-(chloromethyl)-7-methylimidazo[1,2-a]pyridine. To a solution of 5-bromo-4-methylpyridin-2-amine (1000 mg, 5.37 mmol) in DMF (15 mL) was added 1,3-dichloropropan-2-one (2.04 g, 16.1 mmol) at room temperature. The resulting reaction was stirred at 85 °C for 2 hours. The solution was quenched with HO (40 mL), and the pH of the mixture was adjusted to 8 by adding saturated NaHCO solution. The resulting mixture was then extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified using a silica gel column (PE / EtOAc = 1 / 1) to give 6-bromo-2-(chloromethyl)-7-methylimidazo[1,2-a]pyridine (500 mg, yield: 36%) as a pale yellow oil. ESI-MS [M+H] + : 259.2.

[0323] Synthesis of 1-((6-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (I-28). To a solution of 6-bromo-2-(chloromethyl)-7-methylimidazo[1,2-a]pyridine (56 mg, 0.22 mmol) in DMF (3 mL) was added N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (40 mg, 0.14 mmol) and CsCO (140 mg, 0.43 mmol) at room temperature. The resulting reaction was stirred at room temperature for 12 hours. HO (30 mL) was added to the reaction mixture and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (DCM / MeOH = 10 / 1) to give 1-((6-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide (22 mg, yield: 32%) as a white solid. ESI-MS [M+H] + : 498.0. Purity: 98.7%. 1 H NMR (400 MHz, DMSO): δ 8.89 (s,1H), 8.60-8.57 (m, 1H), 8.31-8.29 (m, 2H), 8.22 (s, 1H), 7.87 (s, 1H), 7.78 (s,1H), 7.72 (s, 1H), 7.51 (s, 1H), 6.65 (d, J = 7.4 Hz, 1H), 5.40 (s, 2H), 4.55 (d,J = 5.6 Hz, 2H), 2.36 (s, 3H).

[0324] Example 29 Scheme 29 [ka] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide. A mixture of 1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid (100 mg, 0.62 mmol), 7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (160 mg, 0.74 mmol), HATU (290 mg, 0.78 mmol), and DIPEA (0.32 mL, 1.86 mmol) in DMF (5 mL) was stirred at room temperature for 16 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL × 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH=10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide (60 mg, yield: 30%) as a yellow solid. ESI-MS [M+H] + : 326.1.

[0325] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (I-29). A mixture of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (50 mg, 0.15 mmol), 2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (40 mg, 0.19 mmol), and CsCO (125 mg, 0.39 mmol) in DMF (5 mL) was stirred at room temperature for 4 hours. Water (30 mL) was added and extracted with EtOAc (30 mL x 3). The combined organic layers were concentrated and purified by preparative HPLC to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (9.1 mg, yield: 12%) as a yellow solid. ESI-MS [M+H] +: 496.1. Purity: 86.0%. 1 H NMR (400 MHz, DMSO): δ 9.06 (t,J = 5.8 Hz, 1H), 8.43 (d, J = 4.7 Hz, 1H), 8.40-8.25 (m, 4H), 8.14 (d, J = 8.3 Hz,1H), 7.87 (s, 1H), 7.73 (s, 1H), 7.37 (d, J = 9.4 Hz, 1H), 7.26 (dd, J = 8.3, 4.7Hz, 1H), 6.97 (d, J = 9.4 Hz, 1H), 6.66 (dd, J = 7.4, 2.0 Hz, 1H), 5.59 (s, 2H),4.77 (d, J = 5.7 Hz, 2H), 1.96-1.81 (m, 1H), 0.96-0.83 (m, 2H), 0.73-0.56 (m, 2H).

[0326] Example 30 Scheme 30 [ka] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide. A mixture of 1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid (100 mg, 0.62 mmol), 7-bromoimidazo[1,5-a]pyridin-1-yl)methanamine hydrochloride (190 mg, 0.74 mmol), HATU (350 mg, 0.93 mmol), and DIPEA (0.32 mL, 1.86 mmol) in DMF (5 mL) was stirred at room temperature for 16 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL × 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH=10 / 1) to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (60 mg, yield: 20%) as a yellow solid. ESI-MS [M+H] + : 370.1.

[0327] Synthesis of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (I-30). A mixture of N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (60 mg, 0.16 mmol), 2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (40 mg, 0.19 mmol), and CsCO (125 mg, 0.39 mmol) in DMF (5 mL) was stirred at room temperature for 4 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were concentrated and purified by preparative HPLC to give N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide (13.0 mg, yield: 15%) as a yellow solid. ESI-MS [M+H] + : 540.1. Purity: 89.1%. 1 H NMR (400 MHz, DMSO): δ 9.06 (t,J = 6.0 Hz, 1H), 8.43 (d, J = 3.7 Hz, 1H), 8.36 (d, J = 5.4 Hz, 2H), 8.31-8.22 (m,2H), 8.14 (d, J = 8.0 Hz, 1H), 8.04 (s, 1H), 7.73 (s, 1H), 7.37 (d, J = 9.2 Hz,1H), 7.26 (dd, J = 8.3, 4.7 Hz, 1H), 6.97 (d, J = 9.5 Hz, 1H), 6.81-6.67 (m, 1H),5.59 (s, 2H), 4.77 (d, J = 5.8 Hz, 2H), 1.89 (d, J = 5.1 Hz, 1H), 0.96-0.84 (m,2H), 0.64 (d, J = 5.1 Hz, 2H).

[0328] Example 31 Scheme 31 [ka] Synthesis of methyl 2-((dimethylamino)methylene)-4-methoxy-3-oxobutanoate. A mixture of methyl 4-methoxy-3-oxobutanoate (500 mg, 3.42 mmol) and DMF-DMA (410 mg, 3.42 mmol) in anhydrous DMF (5 mL) was stirred at 110° C. for 10 hours. The mixture was concentrated to give methyl 2-((dimethylamino)methylene)-4-methoxy-3-oxobutanoate (600 mg, 87% yield) as a yellow oil. ESI-MS [M+H] + : 202.1.

[0329] Synthesis of methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate. A solution of methyl 2-((dimethylamino)methylene)-4-methoxy-3-oxobutanoate (600 mg, 3.0 mmol), N2H4·H2O (0.15 mL, 3.0 mmol), and AcOH (0.21 mL, 3.6 mmol) in anhydrous EtOH (10 mL) was stirred at reflux for 12 hours. The mixture was concentrated and purified by preparative TLC (DCM / MeOH = 30 / 1) to give methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate (400 mg, 78% yield) as a brown solid. ESI-MS [M+H] + : 171.1.

[0330] Synthesis of methyl 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylate and methyl 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxylate. A mixture of methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate (100 mg, 0.59 mmol), 2-(chloromethyl)-6-cyclopropylimidazo[1,2-a]pyridine (150 mg, 0.70 mmol), and CsCO (480 mg, 1.48 mmol) in DMF (5 mL) was stirred at room temperature for 16 hours. Water (50 mL) was added, and the mixture was extracted with EtOAc (50 mL × 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH=15 / 1) to give methyl 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylate (100 mg, yield: 50.0%) as a pale yellow solid (ESI-MS [M+H] + : 341.1), and methyl 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxylate (50 mg, yield: 25.0%) as a pale yellow solid (ESI-MS [M+H] + : 341.1) obtained.

[0331] Synthesis of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylic acid. A solution of methyl 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylate (100 mg, 0.29 mmol) and LiOH·HO (40 mg, 0.88 mmol) in THF / MeOH / HO (2 mL / 2 mL / 1 mL) was stirred at 70 °C for 1 h. The solvent was evaporated, and the pH value of the residue was adjusted to 5 by adding 1 M HCl solution. The resulting solid precipitate was filtered to give 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylic acid (90 mg, yield: 94.7%) as a yellow oil, which was used in the next step without purification. ESI-MS [M+H] + : 327.1.

[0332] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxamide (I-31). A mixture of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylic acid (45 mg, 0.14 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (36 mg, 0.17 mmol), HATU (105 mg, 0.28 mmol), and DIPEA (0.1 mL, 0.41 mmol) in DMF (3 mL) was stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxamide (19.6 mg, yield: 29%) as a white solid. ESI-MS [M+H]+ : 490.1. Purity: 97.6%. 1 H NMR (400 MHz, DMSO): δ 8.49 (s,1H), 8.41-8.28 (m, 3H), 8.23 ​​(s, 1H), 7.90 (s, 1H), 7.79 (s, 1H), 7.55 (d, J = 9.0Hz, 1H), 7.29 (s, 1H), 6.66 (d, J = 6.3 Hz, 1H), 5.46 (s, 2H), 4.57 (d, J = 5.2Hz, 2H), 4.53 (s, 2H), 3.20 (s, 3H), 1.99 (s, 1H), 0.97 (d, J = 7.5 Hz, 2H), 0.71(d, J = 5.4 Hz, 2H).

[0333] Example 32 Scheme 32 [ka] Synthesis of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxylic acid. A solution of methyl 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxylate (50 mg, 0.15 mmol) and LiOH·HO (20 mg, 0.44 mmol) in THF / MeOH / HO (2 mL / 2 mL / 1 mL) was stirred at 70 °C for 1 h. The solvent was evaporated, and the pH of the residue was adjusted to 5 by adding 1 M HCl solution. A solid precipitated and was filtered to give 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxylic acid (45 mg, yield: 94.7%) as a yellow oil. ESI-MS [M+H] + : 327.1.

[0334] Synthesis of N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxamide (I-32). A mixture of 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylic acid (45 mg, 0.14 mmol), (7-chloroimidazo[1,5-a]pyridin-1-yl)methanamine (36 mg, 0.17 mmol), HATU (105 mg, 0.28 mmol), and DIPEA (0.1 mL, 0.41 mmol) in DMF (5 mL) was stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were concentrated and purified by preparative TLC (DCM / MeOH = 10 / 1) to give N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxamide (40.0 mg, yield: 59%) as a white solid. ESI-MS [M+H] + : 490.1. Purity: 99.2%. 1 H NMR (400 MHz, DMSO): δ 8.67 (s,1H), 8.58 (s, 1H), 8.44-8.27 (m, 2H), 8.02 (s, 1H), 7.94 (s, 1H), 7.81 (s, 1H),7.67 (s, 1H), 7.52 (s, 1H)...

Claims

1. Formula (I): [C360] or a pharma- ceutically acceptable salt thereof, During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy A is 0 to 4 R A is substituted with a group, Each R A is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy B teeth, [C374] and W 1 , W 2 , W 3 , and W 4 is independently selected from carbon and nitrogen; R 10 , R 11 , R 12 , R 13 , and R 14 are optionally present when attached to a carbon atom, and when present, are halogen, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 1~6 R independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. B corresponds to the appearance of L is -QC(R) 2 -, -C(R) 2 Q-, -QC(Q)-, -C(Q)Q-, -C(R) 2 QC(O)- and -C(O)QC(R) 2 -, each Q is independently, where valence permits, a monovalent or divalent group selected from the group consisting of O, N(R), or S; R 1 , R 2 , R 3 , and R 4 is hydrogen and C 1~6 independently selected from aliphatic, R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; Each R is independently hydrogen, —CN, or C 1~6 an optionally substituted group selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two R groups on the same carbon or nitrogen are taken together with the atoms between them to form a ring selected from a 3-7 membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur, and a 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur; The compound or a pharma- ceutically acceptable salt thereof.

2. L is -QC(R) 2 -, -C(R) 2 Q-, -C(Q)Q-, or -C(R) 2 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein Q is independently selected from O or N(R)-, where valency permits, a monovalent or divalent group.

3. 3. The compound of claim 2, or a pharma- ceutically acceptable salt thereof, wherein L is -N(H)C(O)- or -C(O)N(H)-.

4. L is the following: [C364] [C365] is selected from the group consisting of In the formula, # represents Cy A 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein:

5. L is a group represented by the following formula: [C365-1] where # is Cy A 5. The compound of claim 4, or a pharma- ceutically acceptable salt thereof, wherein:

6. R 3 and R 4 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

7. The compound has the formula (II): [C366] wherein Cy A , Cy B , R 1 , R 2 , R 6 , and R 72. The compound of claim 1, wherein:

8. Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur; Cy A But 0 to 2 R A The compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, which is substituted with a group.

9. Cy A but the following: [C367] is selected from the group consisting of 8. The compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, wherein * represents the point of attachment to L.

10. Cy A but the following: [C367-1] [C367-2] 10. The compound of claim 9, or a pharma- ceutically acceptable salt thereof, wherein * represents the point of attachment to L.

11. The compound has the formula (III-a) to (III-d): [C368] [C369] wherein Cy B , R A , R 1 , R 2 , R 6 , and R 7 2. The compound of claim 1, wherein:

12. Cy B but the following: [C371] 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

13. Each R A But, C 1~6 The compound according to any one of claims 1 to 9 or 11 to 12, or a pharma- ceutically acceptable salt thereof, wherein each of the optionally substituted groups is selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1 to 2 heteroatoms selected from oxygen, nitrogen, or sulfur.

14. R 5 , R 6 , R 7 , R 8 , and R 9 is hydrogen, halogen, -CN, -N(R) 2 , -OR, or C 1~6 an optionally substituted group selected from aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and each R is independently hydrogen or C 1~6 14. The compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof, which is aliphatic.

15. R 6 15. The compound of claim 14, or a pharma- ceutically acceptable salt thereof, wherein is selected from hydrogen or halogen.

16. R 6 16. The compound of claim 15, or a pharma- ceutically acceptable salt thereof, wherein is halogen.

17. R 7 is halogen or optionally substituted C 1~6 17. The compound of claim 15 or 16, or a pharma- ceutically acceptable salt thereof, selected from aliphatic.

18. R 7 18. The compound of claim 17, or a pharma- ceutically acceptable salt thereof, wherein is halogen.

19. The compound has formula IV: [C361] The During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 heteroatoms selected from oxygen or nitrogen; Cy A is 0 to 3 R A is substituted with a group, L is selected from -NC(O)- and -C(O)N-; R 7 is -F, -Cl, or -Br; W 4 is carbon or nitrogen, R 10 and R 11 are each optionally present and, when present, represent halogen, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 1~6 independently selected from optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 13 is halogen, -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 2~6 optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 14 is optionally present and, when present, represents halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 3~6optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R, R A , R 6 , R 7 , and R 8 is as defined in claim 1, 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

20. The compound has formula V: [C362] The During the ceremony, Cy A is a 5-membered heteroarylene having 1 to 4 nitrogen atoms; Cy A When contains three nitrogen atoms, Cy A is a group represented by the formula [C363] rather, * represents the point of attachment to L, R 11 is optionally present and, when present, represents halogen, —CN, —C(R)═N(R), —C(O)R, —C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 , or C 1~6optionally substituted groups selected from aliphatic, phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R 13 is -CN, -C(R)=N(R), -C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -NO 2 , -N(R) -N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)S(O) 2 R, -OR, -OC(O)R, -OC(O)N(R) 2 , -SR, -S(O)R, -S(O) 2 R, -S(O)N(R) 2 , -S(O) 2 N (R) 2 or an optionally substituted group selected from phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 3 or 5-7 membered saturated or partially unsaturated monocyclic carbocyclyl, and 3-7 membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; R, R 6 , R 7 , R 8 , R 9 , R 10 , R 14 and L is as defined in claim 19.

20. The compound of claim 19 or a pharma- ceutically acceptable salt thereof.

21. R 13 is halogen, optionally substituted C 2~620. The compound of claim 19, or a pharma- ceutically acceptable salt thereof, selected from aliphatic, and optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.

22. R 13 22. The compound of claim 21, or a pharma- ceutically acceptable salt thereof, wherein is halogen.

23. R 13 is optionally substituted C 2~6 22. The compound of claim 19 or 21, or a pharma- ceutically acceptable salt thereof, which is aliphatic.

24. R 13 20. The compound of claim 19, or a pharma- ceutically acceptable salt thereof, wherein is an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic carbocyclyl.

25. R 13 21. The compound of claim 20, or a pharma- ceutically acceptable salt thereof, wherein is an optionally substituted 3 or 5-7 membered saturated or partially unsaturated monocyclic carbocyclyl.

26. R 13 22. The compound of claim 20 or 21, or a pharma- ceutically acceptable salt thereof, wherein is optionally substituted cyclopropyl.

27. The compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-methylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-isopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((7-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-methoxyimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5,6-dimethylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-5-(methoxymethyl)-1H-pyrazole-4-carboxamide, N-((7,8-dichloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-chloro-5-ethylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-methylimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-7-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-7-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)thiazole-5-carboxamide, 1-((6-bromo-5-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-bromo-5-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-(2,2-dimethylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-(2-methylprop-1-en-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(2-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(2-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-iodoimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-ethylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, (Z)—N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-(prop-1-en-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-cyclopropylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-(2,2-dimethylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((6-aminoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyanoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyanoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((5-amino-7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclobutylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methoxyimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, methyl 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)propanoate, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-ethynylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-ethylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-thiadiazole-2-carboxamide, Ethyl 2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate, 2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid, 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)propionic acid, N-(1-(7-bromoimidazo[1,5-a]pyridin-1-yl)ethyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-(methylamino)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-3-cyclopropyl-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-ethynylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetate methyl, 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-5-yl)propionic acid methyl ester, N-((7-bromo-3-(difluoromethyl)imidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-3-cyclopropyl-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxyethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-amino-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((5-amino-8-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl-d2)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridine-6-carboxylate methyl, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, Ethyl 3-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)propanoate, N-(2-(7-chloroimidazo[1,5-a]pyridin-1-yl)ethyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(difluoromethyl)-1H-pyrazole-4-carboxamide, 2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridine-6-carboxylic acid, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-N-((7-ethynylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(difluoromethyl)-1H-pyrazole-4-carboxamide, 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)ethyl acrylate, Ethyl 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoate, 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(morpholinomethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(oxetan-3-yl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methoxyethoxy)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((8-acetyl-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-(((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)ethyl acetate, 2-(2-((4-(((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)acetic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxypropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-hydroxy-2-methylpropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, Ethyl 2-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)cyclopropane-1-carboxylate, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, Ethyl 1-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridin-8-yl)cyclopropane-1-carboxylate, 1-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridin-8-yl)cyclopropane-1-carboxylic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(1-(hydroxymethyl)cyclopropyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-vinylimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazol-3-yl)cyclopropane-1-carboxylic acid, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxyoxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N'-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-N-cyano-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboximidamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(1-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methoxyethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 3-((2H-tetrazol-5-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, Ethyl 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)cyclopropane-1-carboxylate, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, 2-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)cyclopropane-1-carboxylic acid, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-methoxyimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-6-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,4-triazole-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-hydroxyoxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, 1-((8-((1,3,4-oxadiazol-2-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, 2-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)ethyl acetate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((8-cyano-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,3,4-oxadiazole-2-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(methylsulfonyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1-methyl-1H-1,2,4-triazole-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-4H-1,2,4-triazole-3-carboxamide, Ethyl 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoate, Ethyl 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoate, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)propanoic acid, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-5-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate ethyl, 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-fluorooxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, Ethyl 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 3-(2-((4-(((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((6-chloro-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-morpholinoimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)isoxazole-3-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-5-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,2,4-oxadiazole-3-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1H-tetrazol-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(4H-1,2,4-triazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-formylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-(3-amino-3-oxopropyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(2-cyanoethyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-ylmethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((6-chloro-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6,7-dichloroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-3-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1,2,4-oxadiazole-5-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(difluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)-1H-pyrazole-4-carboxylic acid, 1-((8-(2-(1H-tetrazol-5-yl)ethyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)oxazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(1-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxotetrahydrofuran-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-((1H-pyrazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)-1H-pyrazole-3-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxopyrrolidin-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-bromo-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoate ethyl, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanoic acid, 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)ethyl acetate, 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)acetic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylpyrazolo[1,5-a]pyrimidin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, ethyl 5-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)-1,3,4-oxadiazole-2-carboxylate, 1-((8-((1,3,4-oxadiazol-2-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)-2-methylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1-fluoroethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-((1,3,4-oxadiazol-2-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(oxetan-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxooxazolidin-3-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1H-pyrazol-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)cyclopentane-1-carboxylate methyl, 1-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)cyclopentane-1-carboxylic acid, 1-((2-((4-(((7-chloro-8-ethoxyimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)methyl)cyclopentane-1-carboxylic acid, ethyl 2-((2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)oxy)-2-methylpropanoate, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-fluoropropanoate methyl, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-fluoropropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(isoxazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-(2-((4-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methylcarbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-1H-imidazole-4-carboxylic acid, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-1H-imidazole-4-carboxylic acid, Ethyl 3-(4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)-3-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)propanoate, 3-(4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)-3-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)propanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-ethynylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-1H-pyrazole-4-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(2-cyano-2-methylpropyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methyl-2-(2H-tetrazol-5-yl)propyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-3-fluoroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-3-hydroxy-2,2-dimethylpropanoate ethyl, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-3-hydroxy-2,2-dimethylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(1-ethyl-5,6-dioxo-5,6-dihydro-1,2,4-triazin-4(1H)-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, ethyl 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-methylpropanoate, 3-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-2-methylpropanoic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(5,6-dioxo-5,6-dihydro-1,2,4-triazin-4(1H)-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, Ethyl 4-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)-4H-1,2,4-triazole-3-carboxylate, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-methyl-4H-1,2,4-triazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-oxa-6-azaspiro[3.3]heptan-6-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((5-chloro-7-cyclopropyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylindolizin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(2-methylthiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(3-methyl-1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, Ethyl 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-2-carboxylate, 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-2-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-cyclopropyl-7-(2-oxopyrrolidin-1-yl)pyrazolo[1,5-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(thiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 4-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-8-yl)morpholine-2-carboxylic acid, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)azetidine-3-carboxylate methyl, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)azetidine-3-carboxylic acid, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)pyrrolidine-3-carboxylate methyl, 1-(2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylimidazo[1,2-b]pyridazin-8-yl)pyrrolidine-3-carboxylic acid, 2-((4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1H-1,2,3-triazol-1-yl)methyl)-6-cyclopropylindolizine-3-carboxylate ethyl, 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrole-2-carboxylate methyl, 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrole-2-carboxylic acid, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxy(3-(hydroxymethyl)oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrrole-3-carboxamide, N-((7-chloro-6-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-(1-(7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)ethyl)-1-(1-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-(1-(7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)ethyl)-1-((6-cyclopropyl-8-(hydroxy(oxetan-3-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-((N-(2,2,2-trifluoroethyl)sulfamoyl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-([1,2,4]triazolo[1,5-a]pyridin-2-ylmethyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-b]pyridazin-2-ylmethyl)-1H-pyrazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-1,2,3-triazole-4-carboxamide, 1-([1,2,4]triazolo[1,5-a]pyridin-2-ylmethyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-imidazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-2H-tetrazole-5-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-b]pyridazin-2-ylmethyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-b]pyridazin-2-ylmethyl)-1H-imidazole-4-carboxamide, 1-((8-(4H-1,2,4-triazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(pyrrolidin-1-ylmethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((8-(oxetan-3-ylmethyl)imidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-imidazole-4-carboxamide, 1-((8-(aminomethyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-((2-(dimethylamino)ethoxy)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-(((3,3,3-trifluoro-2-hydroxypropyl)amino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropyl-8-((2-hydroxyethoxy)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, 1-((8-((2-aminoethoxy)methyl)-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, and N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide 2. The compound of claim 1, selected from:

28. 28. The compound of claim 27, wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

29. 28. The compound of claim 27, wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

30. 28. The compound of claim 27, wherein the compound is N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

31. 28. The compound of claim 27, wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

32. 28. The compound of claim 27, wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

33. 28. The compound of claim 27, wherein the compound is N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

34. 28. The compound of claim 27, wherein the compound is N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

35. 28. The compound of claim 27, wherein the compound is N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

36. 28. The compound of claim 27, wherein the compound is N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6,7-dichloroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide or a pharma- ceutically acceptable salt thereof.

37. 28. The compound of claim 27, wherein the compound is 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-2-carboxylic acid or a pharma- ceutically acceptable salt thereof.

38. 38. A pharmaceutical composition comprising a compound according to any one of claims 1 to 37, or a pharma- ceutically acceptable salt thereof, and further comprising a pharma- ceutically acceptable excipient.

39. 40. A composition comprising a compound according to any one of claims 1 to 37, or a pharma- ceutically acceptable salt thereof, for the treatment of hereditary angioedema or diabetic macular edema.

Citation Information

Patent Citations

  • therapeutic inhibitory compounds

    JP2017520597A

  • Inhibitor of KRAS G12C mutant protein

    JP2019529484A

  • Inhibitors of plasma kallikrein and uses thereof

    JP2020529998A

  • Therapeutic inhibitory compouds

    WO2017001924A1

  • Therapeutic inhibitory compounds

    WO2018011628A1

Cited By

  • Imidazopyridine substitutes as inhibitor of plasma kallikrein and use thereof

    JP2024012697A